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ABSTRACT
Salaheddin, Sharif M. A.. Effects of Creatine Supplementation Protocols and Doxorubicin on
Cardiac and Skeletal Muscle Phosphocreatine System. Published Doctor of Philosophy
Dissertation, University of Northern Colorado, 2021.
Doxorubicin (Dox) is a highly effective anticancer drug used to treat several cancer
types; however, its use is limited due to its cytotoxicity (cardiotoxicity and myotoxicity).
Doxorubicin-induced cardiotoxicity might occur within days and lead to congestive heart failure.
Doxorubicin-induced myotoxicity involves fatigue, cachexia, and skeletal muscle dysfunction.
Although the exact mechanisms causing Dox-induced cytotoxicity are not entirely understood,
an alteration in the phosphocreatine system seems to be a central mechanism where studies
showed Dox decreased phosphocreatine (PCr), creatine (Cr), impaired creatine kinase (CK)
enzyme function, and decreased creatine transporter (CrT) expression in cultured
cardiomyocytes. Ultimately, Dox-induced cytotoxicity might compromise quality of life and
impair activities of daily living in cancer patients. Creatine supplementation is one promising
non-pharmacological therapeutic intervention to alleviate Dox-induced cytotoxicity. One study
showed that two weeks of Cr supplementation alleviated Dox-induced skeletal muscle fatigue;
however, the effects of Cr supplementation on Dox-induced cytotoxicity specific to the
phosphocreatine system have yet to be explored. The purpose of this study was to examine the
effects of different doses of Cr supplementation before Dox treatment on mitochondrial CK
(MtCK), cytosolic CK (CK-M), and creatine transporter (CrT) expression in cardiac and skeletal
muscle. Sixty male rats were randomly assigned to one of two, four-week Cr feeding
interventions (standard Cr diet or Cr loading diet) or a control diet group (Con, n = 20). Rats in
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the standard Cr diet (Cr1, n = 20) were fed 2% Cr for four weeks. Rats in the Cr loading diet
(Cr2, n = 20) were fed 4% Cr for one week followed by 2% Cr for three weeks. After four weeks
of feeding, rats received either a bolus 15 mg/kg Dox injection or a saline injection as a placebo
(Sal). Five days following injections, left ventricle (LV), extensor digitorum longus (EDL),
soleus (SOL), and diaphragm (DIA) were excised, weighed, and western blotting was performed
to quantify MtCK, CK-M, and CrT expression. Enzyme-linked immunosorbent assays (ELISA)
was done to verify western blot results. No significant main effects or interactions were observed
for CK-M and CrT expression in LV but a significant drug effect was observed for MtCK with
Con+Dox, Cr1+Dox, and Cr2+Dox expressing significantly lower MtCT than Con+Sal (p <
0.05). Enzyme-linked immunosorbent assays showed a main drug effect and a diet x drug
interaction for MtCK in LV. In EDL, SOL, and DIA muscle, no main effects or interactions were
observed for MtCK, CK-M, or CrT expression. Doxorubicin treatment decreased cardiac MtCK
expression but Cr supplementation did not protect against these alterations. Impairments in
MtCK might play a role in Dox-induced cardiotoxicity but nutritional Cr supplementation did
not seem to provide protection. Further work should explore additional interventions to protect
against Dox-induced MtCK changes.

iv

TABLE OF CONTENTS
CHAPTER I. INTRODUCTION TO THE STUDY ................................................................1
Background ...................................................................................................................1
Statement of Purpose ....................................................................................................7
Research Hypotheses ....................................................................................................8
Need for the Study ........................................................................................................8
Preliminary Data ............................................................................................................9
CHAPTER II. REVIEW OF LITERATURE ..........................................................................13
Purpose of the Study ....................................................................................................13
The Phosphocreatine Creatine Kinase System ............................................................13
Doxorubicin .................................................................................................................22
Doxorubicin-Induced Cardiotoxicity ...........................................................................24
Doxorubicin-Induced Myotoxicity ..............................................................................30
Exercise and Doxorubicin ...........................................................................................36
Creatine and Creatine Metabolism...............................................................................38
Creatine Supplementation ............................................................................................39
The Therapeutic Role of Creatine in Diseases and Disorders .....................................43
Creatine and Cancer .....................................................................................................50
Creatine and Doxorubicin ...........................................................................................53
Conclusion ...................................................................................................................54
CHAPTER III. METHODOLOGY .........................................................................................56
Purpose of the Study ....................................................................................................56
Experimental Design ...................................................................................................56
Animals ........................................................................................................................57
In Vivo Muscle Function .............................................................................................59
Tissue Collection and Storage .....................................................................................60
Biochemical Analyses .................................................................................................60
Data Analysis ...............................................................................................................63
CHAPTER IV. RESULTS .......................................................................................................64
Purpose of the Study ....................................................................................................64
Amount of Food Intake ................................................................................................64
Animal Characteristics .................................................................................................65

v

In Vivo Muscle Function .............................................................................................66
Biochemical Analyses .................................................................................................67
CHAPTER V. DISCUSSION AND CONCLUSIONS ...........................................................77
Purpose of the Study ....................................................................................................77
Discussion ....................................................................................................................77
REFERENCES .......................................................................................................................91
APPENDIX. INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE
APPROVAL .............................................................................................................167

vi

LIST OF TABLES
1.

Amount of Food Intake ................................................................................................65

2.

Animal Characteristics .................................................................................................66

vii

LIST OF FIGURES
1.

Left Ventricle Mitochondrial Creatine Kinase Expression ..........................................10

2.

Left Ventricle Cytosolic Creatine Kinase Expression ................................................11

3.

Left Ventricle Creatine Transporter Expression .........................................................12

4.

Experimental Design ....................................................................................................59

5.

Forelimb Grip Strength Test ........................................................................................67

6.

Left Ventricle Mitochondrial Creatine Kinase Expression ..........................................68

7.

Left Ventricle Cytosolic Creatine Kinase Expression .................................................69

8.

Left Ventricle Creatine Transporter Expression ..........................................................70

9.

Extensor Digitorum Longus Muscle Mitochondrial Creatine Kinase Expression.......71

10.

Extensor Digitorum Longus Muscle Cytosolic Creatine Kinase Expression ..............71

11.

Extensor Digitorum Longus Muscle Creatine Transporter Expression .......................72

12.

Soleus Muscle Mitochondrial Creatine Kinase Expression .........................................72

13.

Soleus Muscle Cytosolic Creatine Kinase Expression ................................................73

14.

Soleus Muscle Creatine Transporter Expression .........................................................73

15.

Diaphragm Muscle Mitochondrial Creatine Kinase Expression .................................74

16.

Diaphragm Muscle Cytosolic Creatine Kinase Expression .........................................74

17.

Diaphragm Muscle Creatine Transporter Expression ..................................................75

18.

Left Ventricle Mitochondrial Creatine Kinase Enzyme-Linked
Immunosorbent Assay .................................................................................................76

viii

1

CHAPTER I
INTRODUCTION TO THE STUDY
Background
According to the American Cancer Society, more than 1.8 million new cancer cases are
expected to be diagnosed in 2021 with approximately 608,570 patients dying from cancer in the
United States (Siegel et al., 2020, 2021). Cancer is a central public health problem worldwide
and is the second leading cause of death after cardiovascular disease in the United States. It is
still known as the leading cause of death in numerous states, in Hispanic and Asian Americans,
and in individuals younger than 80 years old (Heron & Anderson, 2016; Siegel et al., 2015).
Since 1991, the cancer death rate has declined by about 29% (Siegel et al., 2020), which suggests
the number of cancer patients receiving anticancer treatment is also increasing. Three types of
cancer treatment options are currently available: surgery, radiation, and pharmacological therapy.
Pharmacological therapy includes chemotherapy, targeted therapy, immunotherapy, hormone
therapy, and other supportive medications (Siegel et al., 2012).
Doxorubicin (Dox, trade name Adriamycin) is an anthracycline antibiotic chemotherapy
drug that is extracted from Streptomyces peucetius and is used in the treatment of several cancers
including breast, lung, gastric, ovarian, thyroid, lymphoma, multiple myeloma, sarcoma, and
pediatric cancers (Cortés-Funes & Coronado, 2007; Thorn et al., 2011; Weiss, 1992).
Doxorubicin's primary function is to halt the cell cycle and damage deoxyribonucleic acid
(DNA), thus preventing cancer cell division. Doxorubicin has anticancer effects as it intercalates
DNA, disrupts topoisomerase enzymes, and generates free radicals causing membrane lipid,
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DNA, and protein damage in cancer cells (Gewirtz, 1999; Thorn et al., 2011). Even though Dox
is one of the most widely prescribed and effective cytotoxic drugs used in oncology, its use is
limited due to its side effects and toxicities including cardiotoxicity, myotoxicity, fatigue, hair
loss, vomiting, and neutropenia (Cortés-Funes & Coronado, 2007; Gilliam & Clair, 2011;
Hydock et al., 2011; Shi et al., 2011; Thorn et al., 2011). These toxicities compromise quality of
life and impair activities of daily living (ADLs) in cancer patients receiving Dox.
Doxorubicin-induced cardiotoxicity has two manifestations: acute toxicity and chronic
toxicity. The incidence of acute cardiac toxicity in patients is about 11% and might occur within
three days of Dox treatment (Chatterjee et al., 2010; Takemura & Fujiwara, 2007). Chronic
cardiac toxicity causes progressive myocardial damage and dilated cardiomyopathy, which might
cause congestive heart failure (CHF; Chatterjee et al., 2010; Swain et al., 2003). Congestive
heart failure's manifestations and symptoms include low ejection fraction, low cardiac output,
shortness of breath, drowsiness, lack of energy, and generalized pain, which lead to
compromised quality of life (Blinderman et al., 2008). The incidence of Dox-induced
cardiotoxicity is mainly dependent on its dose with an incidence of around 4% with a cumulative
Dox dose of 500–550 mg/m2, 18% with a Dox dose of 551–600 mg/m2, and 36% when the dose
exceeded 600 mg/m2 (Chatterjee et al., 2010). Although the exact mechanisms causing Doxinduced cardiotoxicity are not entirely understood, several studies showed that Dox treatment led
to the generation of cardiac reactive oxygen species (ROS) and lipid peroxidation (Chatterjee et
al., 2010; Tacar et al., 2013; Thorn et al., 2011). Increased ROS production induces damage to
mitochondria of cardiomyocytes by increasing superoxide formation (Kotamraju et al., 2000).
Superoxide and other ROS may lead to apoptosis in cardiomyocytes by inducing p53 (Chatterjee
et al., 2010; Kalyanaraman et al., 2002; Kotamraju et al., 2000). It was suggested Dox treatment
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leads to the downregulation of cardiac α-actin, myosin light and heavy chains, troponin-I, and
desmin proteins contributing to cardiac dysfunction (Chatterjee et al., 2010).
An alteration in energy metabolism (i.e., phosphocreatine creatine kinase [PCr/CK]
system) also seems to be a central mechanism of Dox-induced cardiotoxicity. Briefly, the
PCr/CK system consists of creatine (Cr), creatine kinase (CK), and phosphocreatine (PCr),
which plays a central role in cellular energy buffering and energy transport mainly in cells with
high energy requirements such as in skeletal and cardiac muscle (Guimarães-Ferreira, 2014). The
PCr/CK system is essential in promoting rapid resynthesis of adenosine triphosphate (ATP)
through CK action (Guimarães-Ferreira, 2014; Sahlin & Harris, 2011). Several studies showed
that some of the consequences of Dox treatment included compromised mitochondrial function
such as impaired respiration and generation of high-energy phosphates as well as decreased PCr,
Cr, ATP, PCr/Cr ratio, PCr/ATP ratio, decreased CK enzyme expression, and impaired CK
enzyme function in cardiac muscle cells (Jeyaseelan et al., 1997; Nicolay et al., 1987; Nicolay &
de Kruijff, 1987; Schlattner et al., 2006; Tokarska-Schlattner et al., 2002, Tokarska-Schlattner,
Wallimann et al., 2006; Tokarska-Schlattner, Zaugg et al., 2006; Tokarska-Schlattner, Walliman
et al., 2005). Furthermore, one study showed that acute exposure to a low dose of Dox rapidly
reduced Cr transport by decreasing creatine transporter (CrT) expression in cultured
cardiomyocytes (Darrabie et al., 2012). The reduction of PCr, Cr, PCr/ATP ratio, CK enzymes,
and CrT might, therefore, lead to impairments in the PCr/CK system and energy metabolism in
cardiac muscle cells. This suggested a potential role of the PCr/CK system as a significant
therapeutic target for alleviating Dox-induced cardiotoxicity in cancer patients.
With skeletal muscle, Dox-induced myotoxicity manifests itself as muscle dysfunction,
fatigue, and cachexia (Bredahl & Hydock, 2016; Bredahl et al., 2016; Hydock et al., 2011; van
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Norren et al., 2009). Skeletal muscle dysfunction induced by Dox treatment includes
impairments in maximal twitch force, maximal rate of force development, maximal rate of force
decline, and increased fatigue (Hydock et al., 2011). Doxorubicin might play a role in the onset
of cachexia, or muscle wasting, in cancer patients, affecting 50–80% of cancer patients and
accounting for approximately 20% of cancer-related deaths (Argilés et al., 2014; Vaughan et al.,
2013). A recent meta-analysis showed Dox treatment caused skeletal muscle atrophy with
reduced skeletal muscle mass and muscle strength (Hiensch et al., 2019). Also, Dox treatment
resulted in reduced body mass and impaired skeletal muscle function in a dose-dependent
manner that was shown to be related to cardiac function (Hydock et al., 2011). Doxorubicininduced myotoxicity results from direct toxic effects on skeletal muscle but the indirect effects
might be due to reduced blood flow to the skeletal muscles caused by Dox-induced
cardiotoxicity (Hydock et al., 2011).
Even though the main mechanisms causing Dox-induced myotoxicity are not entirely
understood, several studies found Dox treatment increased ROS generation, thereby activating
caspases linked to apoptosis pathways in skeletal muscle (Chatterjee et al., 2010; Tacar et al.,
2013; Thorn et al., 2011; Timolati et al., 2006; Wang et al., 2001). Apoptosis leads to cellular
and protein degradation, which might explain the skeletal muscle dysfunction and atrophy
observed with Dox-induced myotoxicity (He et al., 2009). Additionally, several studies reported
Dox treatment might alter calcium (Ca2+) homeostasis through impaired intracellular Ca2+ release
and uptake mechanisms by reducing sarcolemmal-dihydropyridine- sensitive Ca2+ channel
activity, decreasing specific isoforms of sarco-endoplasmic reticulum Ca2+-ATPase (SERCA),
and increasing Ca2+ release by the ryanodine receptor at the sarcoplasmic reticulum (SR; Ertunc
et al., 2009; van Norren et al., 2009; Zorzato et al., 1985). Calcium homeostasis plays a
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significant role in regulating skeletal muscle contraction and relaxation and, therefore,
impairment in Ca2+ homeostasis helps explain one element of Dox-induced myotoxicity (SzentGyörgyi, 1975; Wakabayashi, 2015). Even though several preclinical studies examined many
mechanisms of Dox-induced myotoxicity, studies have not explored the effect of Dox treatment
on energy metabolism and the PCr/CK system, which might be a central mechanism of Doxinduced myotoxicity.
Due to the negative impact of Dox on cancer patients, there is now a push to explore nonpharmacological therapeutic interventions that could alleviate Dox-induced cytotoxicity.
Interventions to minimize Dox-induced cytotoxicity are crucial and approaches showing promise
include exercise and nutritional supplementation interventions. Studies have shown exercise
alleviates Dox-induced myotoxicity by preserving maximal twitch force, decreasing oxidative
stress, and minimizing Dox-induced muscle fatigue (Bredahl et al., 2016; Smuder et al., 2011b;
Van Moll et al., 2016). Additionally, several preclinical studies found exercise before Dox
treatment protected against acute cardiotoxicity (Hydock et al., 2008; Wonders et al., 2008);
however, exercise interventions could be challenging because exercise adherence is typically low
in cancer patients undergoing treatment as well as in patients who recently completed treatment
(Courneya et al., 2007; Furmaniak et al., 2016). Furthermore, it was reported that only 30-40%
of newly diagnosed cancer patients met the minimum recommendations for physical activity,
which makes exercise interventions more challenging following diagnosis (Iyer et al., 2016).
This led to the exploration of non-exercise interventions to alleviate Dox-induced cytotoxicity
that could have a high adherence rate in cancer patients receiving it. Supplementing the diet with
creatine as a non-pharmacological therapeutic intervention to alleviate Dox-induced cytotoxicity
is one possible intervention.
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Creatine supplementation has been recognized as one of the most popular nutritional
ergogenic aids for athletes (Kreider et al., 2017). Creatine has been extensively studied in this
context and the most commonly used form is creatine monohydrate (Jäger et al., 2011). Creatine
monohydrate supplementation has been determined to be safe and has pleiotropic therapeutic
benefits in healthy and diseased populations (Kreider et al., 2017). Several studies found Cr
supplementation was also highly beneficial in several muscular, neurological, and cardiovascular
diseases like muscular dystrophies, Huntington’s disease, Parkinson’s disease, and amyotrophic
lateral sclerosis (Bender, Samtleben et al., 2008; Dedeoglu et al., 2003; Landoni et al., 2016;
Louis et al., 2003; Sharov et al., 1987). Furthermore, one study showed that six weeks of Cr
supplementation increased body weight and skeletal muscle strength in heart failure patients
(Kuethe et al., 2006). One preclinical study also showed that Cr supplementation had an
antioxidant effect and slowed tumor growth (Deminice et al., 2016), which would provide added
benefit to cancer patients. Although several studies confirmed the potential therapeutic benefits
of Cr supplementation in various diseases, the main mechanisms of pleiotropic therapeutic
effects of Cr supplementation are not well understood. Several studies confirmed Cr had an
antioxidant effect and decreased ROS generation (Guimarães-Ferreira et al., 2012; Lawler et al.,
2002; Sestili et al., 2006, 2011). The other potential therapeutic mechanism of Cr
supplementation is to enhance the PCr/CK system by increasing muscle Cr and PCr, thereby
enhancing phosphorylation of ADP into ATP by the CK enzymes (Hespel et al., 2001).
Until now, few studies have explored the effect of Cr supplementation on Dox-induced
cytotoxicity. One study showed that Cr supplementation protected against Dox-induced
cytotoxicity by decreasing ROS generation and inhibiting apoptosis in cultured cardiomyocytes
(Santacruz et al., 2015). Using an ex vivo model, it was also demonstrated that incubating
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skeletal muscles in Cr before Dox treatment protected against skeletal muscle dysfunction and
fatigue (Bredahl & Hydock, 2017). It was recently reported that two weeks of feeding with Cr
(rodent chow supplemented with 3% Cr) before Dox treatment in the rat protected against Doxinduced grip strength reduction and lessened the severity of muscle fatigue (Torok et al., 2020).
When combining resistance exercise and Cr supplementation, one study found the combination
provided added protection against Dox-induced skeletal muscle fatigue in the rat when compared
to either intervention alone (Bredahl, Busekrus et al., 2020). With these promising findings, it
was imperative to explore mechanisms behind creatine's protection against Dox cardiac and
skeletal muscle toxicity, and one possible mechanism was the PCr/CK system. More specifically,
examining the impact on CK enzymes and CrT expression in cardiac and skeletal muscles from
Dox treated animals would provide a possible means of elucidating the specific benefits Cr might
have on Dox-induced cytotoxicity. At this point, no studies have examined the effects of Cr
supplementation on Dox-induced cytotoxicity through the PCr/CK system. Understanding the
underlying mechanisms of a Cr supplement's potential therapeutic effects is fundamental to help
find and develop non-pharmacological interventions to prevent and alleviate Dox-induced
cytotoxicity in cancer patients.
Statement of Purpose
The purpose of this study was to examine the effects of different doses of dietary creatine
supplementation before doxorubicin treatment on CK enzymes and CrT protein expression in
cardiac and skeletal muscle.
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Research Hypotheses
H1

Doxorubicin treatment alone will decrease mitochondrial CK enzyme (MtCK),
cytosolic CK enzyme (CK-M), and CrT protein expression in cardiac and skeletal
muscle.

H2

Supplementing the diet with a low dose of Cr monohydrate will increase MtCK
enzyme, CK-M enzyme, and CrT protein expression in cardiac and skeletal
muscle.

H3

Supplementing the diet with a high loading dose of Cr monohydrate will promote
a greater increase in MtCK enzyme, CK-M enzyme, and CrT protein expression
than supplementing the diet with a low dose of Cr monohydrate in cardiac and
skeletal muscle.

H4

Both Cr monohydrate protocols will alleviate Dox-induced decreases in MtCK
enzyme, CK-M enzyme, and CrT protein expression in cardiac and skeletal
muscle.

H5

Supplementing the diet with a high loading dose of Cr monohydrate will have a
greater impact on alleviating Dox-induced decreases in MtCK enzyme, CK-M
enzyme, and CrT protein expression than supplementing the diet with a low dose
of Cr monohydrate.
Need for Study

Cancer mortality rate is expected to decline by approximately 29% (Siegel et al., 2020),
indicating the number of cancer patients treated with chemotherapy drugs such as Dox would
also increase. Doxorubicin treatment has several side effects including cardiotoxicity and
myotoxicity (Gilliam & Clair, 2011; Hydock et al., 2011; Shi et al., 2011; Swain et al., 2003;
Thorn et al., 2011) and these side effects have led to decreases in ADLs and compromised
quality of life for cancer patients (Gilliam & Clair, 2011; Iyer et al., 2016; Schwartz, 2000).
Therefore, it is crucial to find interventions that alleviate Dox-induced cytotoxicity and improve
cancer patients' quality of life. Exercise is an effective intervention and several studies have
shown that exercise alleviated cardiotoxicity and myotoxicity induced by Dox treatment
(Bredahl et al., 2016; Hydock et al., 2008; Van Moll et al., 2016; Wonders et al., 2008);
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however, adherence to exercise is typically low in cancer patients (Courneya et al., 2007;
Furmaniak et al., 2016; Iyer et al., 2016). Because exercise as an intervention might be
challenging for cancer survivors, it is imperative to explore other non-pharmacological
interventions that could alleviate Dox-induced cytotoxicity and have a high adherence rate in
cancer patients receiving Dox.
Supplementing the diet with creatine as a non-pharmacological therapeutic intervention
to alleviate Dox-induced cytotoxicity is one possible intervention. Even though several studies
confirmed the potential therapeutic benefits of Cr supplementation in many diseases (Persky &
Brazeau, 2001), few studies examined the effect of Cr supplementation on Dox-induced
cytotoxicity. Among those, none examined Cr supplementation's effects in alleviating Doxinduced cytotoxicity through the PCr/CK system. Understanding the underlying mechanisms of
Cr supplementation's potential therapeutic effects is fundamental to find and create a nonpharmacological intervention to prevent and alleviate Dox-induced cytotoxicity in cancer
patients. This study was the first preclinical study that explored the effects and mechanisms of Cr
supplementation on Dox-induced cytotoxicity through the PCr/CK system, which could benefit
cancer patients receiving Dox.
Preliminary Data
Twenty male Sprague-Dawley rats (10 weeks old) were randomly assigned to a
doxorubicin group (Dox, n = 10) or a control group (Con, n = 10). Rats in the Dox group
received a bolus 15 mg/kg of Dox injection and Con group rats received an equivalent volume
sterile saline injection. Five days after injections, rats were anesthetized using sodium
pentobarbital (50 mg/kg). After a tail pinch reflex was absent, the heart was excised and the aorta
was cannulated and flushed of blood with Krebs–Hansleit (KH) buffer. The left ventricle (LV)
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was then isolated, weighed, and immediately flash-frozen in liquid nitrogen and stored at -80°C
for ensuing biochemical analysis. Western blot analysis was performed and a C-Digit imager
(LI-COR Biosciences: Lincoln, NE) was used to quantify CK-M, MtCK, and CrT expression in
LV tissue. Data were presented as mean ± standard error (mean ± SEM). An unpaired t-test was
used to determine the difference between groups. Significance was set at the α = 0.05 level.
The Dox group had a significant decrease in MtCK expression when compared to the
Con group (see Figure 1; p < .05). Although CK-M and CrT expression in the Dox group was
lower, about 24.9% and 23.1%, respectively, than the Con group, these differences were not
significant (see Figures 2 and 3; p > .05).

Figure 1

MtCK Expression (OD)
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4

3

2

*

1

C
on

D
ox

0

MtCK 43KDa
GAPDH 37KDa

Note. MtCK= mitochondrial creatine kinase enzyme; Dox = Doxorubicin, n = 10; Con = Control,
n = 10. *Significantly lower than Con (p < .05).
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Figure 2

CK-M Expression (OD)
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Note. CK-M = cytosolic creatine kinase enzyme; Dox = Doxorubicin, n = 10; Con = Control, n =
10.

Following five days of injections, preliminary data showed Dox treatment significantly
decreased MtCK expression in cardiac muscle (see Figure 1). Even though there was a trend
toward reduced CK-M and CrT expression with Dox treatment, Dox treatment did not
significantly decrease CK-M and CrT expressions in cardiac muscle (see Figures 2 and 3).
Doxorubicin-induced decreases in MtCK might disturb ATP production in the mitochondria,
leading to impairment in cellular energy homeostasis and the energy shuttle system in
cardiomyocytes.
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Figure 3
Left Ventricle Creatine Transporter Expression
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Note. CrT = creatine transporter; Dox = Doxorubicin, n = 10; Con = Control, n = 10.
These data suggest MtCK impairments might play a role in Dox-induced cardiotoxicity.
Due to the negative impact of Dox on the cardiac muscle, it is imperative to explore and
understand the role of the CK isoforms and CrT in Dox-induced myotoxicity. To further explore
the effects of Dox treatment on the PCr/CK system, it is also essential to examine Dox
treatment's acute effect on the PCr/CK system in the skeletal muscle. In considering these data,
further exploration is needed to investigate the effect of different Cr supplementation doses on
CK-M, MtCK, and CrT expressions in cardiac and skeletal muscles treated with Dox. The data
collected in a study of this sort would be useful in beginning to illuminate and understand the
underlying mechanisms of Cr supplementation in alleviating Dox-induced cytotoxicity.
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CHAPTER II
REVIEW OF LITERATURE
Purpose of the Study
The purpose of this study was to examine the effects of different doses of dietary creatine
supplementation before doxorubicin treatment on CK enzymes and CrT protein expression in
cardiac and skeletal muscle.
The Phosphocreatine Creatine Kinase System
The PCr/CK system serves as a fast mobilizable reserve of high-energy phosphates in
skeletal muscle, cardiac muscle, and the brain to replenish ATP (Sahlin & Harris, 2011). The
PCr/CK system consists of CK enzymes, PCr, and Cr, which plays a central role in cellular
energy buffering and energy transport mainly in cells with high energy requirements such as in
skeletal muscles, cardiac muscle, brain, and other tissues (Sahlin & Harris, 2011; Saks, 2008;
Saks et al., 2000; Wallimann et al., 2011). Adenosine triphosphate is the cell's primary energy
currency and its hydrolysis is highly exergonic; it consists of three components: a nitrogenous
base (adenine), the sugar ribose, and the triphosphate group (Agteresch et al., 1999). The
maintenance of cell homeostasis depends on mechanisms that regulate ATP production
according to ATP demand. Therefore, cell bioenergetic systems function requires that ATP be
produced and sent to the sites of use and be coupled with removing its hydrolysis products
(Guimarães-Ferreira., 2014). Adenosine triphosphate hydrolysis occurs at different locations like
myosin ATPase in the cytoplasm of muscles, the plasma membrane sodium-potassium adenosine
triphosphatase (Na+/K+ ATPase), SERCA, and Calcium ATPase (Ca2+ ATPase).
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Adenosine triphosphate is converted into adenosine diphosphate (ADP), inorganic
phosphate (Pi), and hydrogen ion (H+) by ATPase enzyme (Agteresch et al., 1999). Rapid
accumulation of ADP, Pi, and H+ inhibit ATPase, such as the myofibrillar actomyosin ATPase
and, consequently, muscle contraction and many other cellular processes (Wallimann et al.,
2011). The PCr/CK system is essential in promoting rapid resynthesise of ATP and reducing
large increases in ADP and H+ through the CK action (Guimarães-Ferreira, 2014; Sahlin &
Harris, 2011). The creatine kinase enzymes catalyze and enhance the reversible reaction by
binding PCr with ADP and H+ to produce ATP and Cr (Wallimann et al., 1992). Therefore, the
PCr/CK system plays a critical role in regulating ATP hydrolysis and prevents the rising of ADP,
Pi, and H+. The transferring of ATP from the mitochondria to the cytosol by the PCr protects the
cell from a decrease in energy supply and acts as a pH buffer by preventing H+ accumulation.
The energy-sparing effects of PCr come from its ability to preserve ATP availability and prevent
the excessive buildup of ADP, which could alter the rate of energy-dependent actions like crossbridge cycling (Sahlin & Harris, 2011; Wallimann et al., 2011; Wyss & Kaddurah-Daouk, 2000).
Remarkably, the PCr/CK system is able to connect ATP production (glycolysis and
oxidative phosphorylation) with subcellular sites of ATP consumption (Guimarães-Ferreira,
2014; Wallimann et al., 2011) and, therefore, it acts as a shuttle system. The mitochondrial and
cytoplasmic compartments are interconnected by an organized energy transfer system founded
by different CK isoforms; thus, the foundations for PCr shuttle theory were established, formally
proposed by Bessman in 1972 (Bessman & Geiger, 1981). The PCr/CK system has different
tissue and cell-specific CK isoforms with distinct subcellular locations (Wallimann et al., 1992).
The CK enzymes are classified into cytosolic and mitochondrial isoforms, which are encoded by
separate nuclear genes and localized differentially on a subcellular level, and these specific
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locations are essential for the functioning of the CK network (Guimarães-Ferreira, 2014;
Wallimann et al., 1992, 2011). Interestingly, the CK-M isoforms are subdivided into muscle-type
CK (M-CK) and brain-type CK (B-CK) form homodimers or heterodimers (e.g., MMCK in
skeletal muscle, MM-CK, MB-CK and BB-CK in cardiac muscle, or BB-CK in the brain, and
many other tissues; Jacobs et al., 1964; Wallimann et al., 1992, 2007). The mitochondrial CK is
located between the inner and outer membrane of the mitochondria; the MtCK isoforms are also
subdivided into sarcomeric MtCK (sMtCK) and found mainly in muscle tissue and ubiquitous
MtCK (uMtCK) expressed in many tissues (Wallimann et al., 1992, 2007, 2011). The CK
isoforms are localized differentially on a subcellular level and these specific locations are critical
for the working of the CK circuit (Wallimann et al., 2007). In the shuttle system, high-energy
phosphate is transferred from the ATP formed by oxidative phosphorylation (OP) in the
mitochondria to Cr through the action of the MtCK, which generates PCr and ADP. The PCr
diffuses into the cytoplasm at the ATP demand sites where CK-M catalyzes the reaction and
generates ATP and Cr. The ATP is then used by the ATPases while Cr returns to the
mitochondria (Bessman & Geiger, 1981; Guimarães-Ferreira, 2014; Wallimann et al., 1992).
Therefore, the CK isoforms contribute to generating a large intracellular pool of PCr that
represents an efficient temporal energy buffer and prevents a rapid fall in global ATP
concentrations.
The PCr/CK system provides a temporal and spatial energy buffer to maintain cellular
energy homeostasis in muscle tissue and cells of high and fluctuating energy requirements
(Wallimann et al., 2011). Creatine kinase enzymes maintain high local ATP/ADP ratios in the
vicinity of cellular ATPases and, on the other hand, a relatively low ATP/ADP ratio in the
mitochondrial matrix to stimulate OP. Inside the cell, PCr/Cr and ATP/ADP ratio stabilities are
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adjusted by CK isoforms. Once Cr enters the muscle tissue through the CrT, it is phosphorylated
to the PCr by the action CK at ATP production by the CK-M coupled to glycolysis or by the
MtCK coupled to the OP (Speer et al., 2004; Straumann et al., 2005; Wallimann et al., 2011).
The mitochondrial ATP, produced by OP, is trans-phosphorylated into PCr by MtCK and leaves
the mitochondria to the cytosol (Dolder et al., 2003; Wallimann et al., 2011). This route of ATP
generation is most important for replenishing the PCr energy store in oxidative tissues. The PCr
is then converted to Cr and ATP by CK-M isoform-associated with ATP-consuming processes,
such as the myofibrillar actomyosin ATPase, SERCA, and Na+/K+-ATPase. The large PCr pool
is used as a temporal energy buffer to maintain constant global and local ATP/ADP ratios over a
wide range of workloads. The higher diffusible PCr, as compared to ATP, together with
localized CK isoforms, is used for spatial energy buffering (Schlattner et al., 2006; Wallimann et
al., 2011). In muscle tissue, the CK isoforms, diffusible PCr, and Cr maintain a high-energy
PCr/Cr-circuit between ATP- producing sites and ATP-consuming processes. Therefore, the
shuttle's energy-producing and consuming sites are connected via PCr and Cr, with no
mandatory need for ATP or ADP to diffuse (Wallimann et al., 2011). It also showed that PCr and
Cr diffusion's mean distance is much higher than that of ATP and ADP (Yoshizaki et al., 1990).
Interestingly, in muscle, the CK-M is concentrated at the myofibrillar I-band and coupled
with the glycolytic enzyme complex (Kraft et al., 2000). The CK-M is associated with the ATP
producer enzyme pyruvate kinase (PK) and the regulatory enzyme phosphofructokinase (PFK),
which is inhibited by ATP accumulation (Dillon & Clark, 1990; Kraft et al., 2000). The
interaction between CK-PFK depends mainly on the pH level; for example, in working muscle,
the pH drop enhances CK-PFK interaction. The ATP is rapidly removed from the glycolytic
compartment and phosphorylated into PCr by the CK-M, which prevents ATP accumulation in
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the glycolytic compartment and inhibits negative feedback inhibition glycolysis through PFK.
The glycolytic ATP is used concurrently to decrease the PCr pool depletion during contraction
(Kraft et al., 2000; Wallimann et al., 2007). Also, the glycolytic ATP is used to replenish the PCr
pool, although not to the maximal extent (van Ginneken et al., 1995; Van Waarde et al., 1990).
In the mitochondria, MtCK forms homo-dimers and homo-octamers, with the latter being
the predominant oligomeric form in vivo (Wallimann et al., 2011). The MtCK is specifically
located in the intermembrane space of mitochondria with preferential access to ATP generated
by the OP via adenine nucleotide translocator (ANT) mitochondrial inner membrane. The ANT
is a protein complex located in the inner mitochondrial membrane and facilitates the exchange of
mitochondrial ATP and cytosolic ADP (Fiore et al., 1998). The mitochondrial CK octamer is
founded in two locations (Maniti et al., 2009). In the first location, the MtCK simultaneously
binds to the inner and outer membrane due to its symmetrical octameric structure and where it
functionally associates with ANT and voltage-dependent anion channel (VDAC) on the outer
membrane. The octamers of MtCK also directly bind to acidic phospholipids cardiolipin in the
inner mitochondrial membrane (Schlattner et al., 2001, 2004).
The second location in the cristae, MtCK, is associated with the inner membrane and
ANT only (Schlattner et al., 2006; Wallimann et al., 1992, 2011). The affinity of both ANT and
MtCK for cardiolipin situates them in standard cardiolipin patches, which can also be induced by
membrane-bound MtCK allowing a functional interaction between both proteins (Epand,
Tokarska-Schlattner et al., 2007; Wallimann et al., 1998). The ATP produced by OP through the
F0F1-ATPase is transported through the inner membrane by ANT in exchange for ADP, where
ATP could either leave the mitochondrion directly by VDAC or will be trans-phosphorylated
into PCr by octameric MtCK in the intermembrane space. Phosphocreatine then leaves the
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mitochondrion through VDAC and feeds into the sizeable cytosolic PCr pool. The ADP
produced from the MtCK trans-phosphorylation reaction is immediately transported back by
ANT into the matrix to be recharged (Patra et al., 2012; Wallimann et al., 2007, 2011). In cristae,
only ATP/ADP exchange is facilitated through direct channeling to the MtCK active site, while
Cr and PCr diffuse along the cristae space to reach VDAC (Schlattner et al., 2006; Wallimann et
al., 2007, 2011). An association of ANT and MtCK causes saturation of MtCK with ANT
delivering ATP and, at the same time, to a locally high ATP/ADP ratio in the vicinity of MtCK.
In combination with the influx of cytosolic Cr through VDAC, which drives the synthesis of PCr
from ATP by MtCK without loss of energy content. This maintains maximal thermodynamic
efficiency for high-energy phosphate synthesis and channeling, which is exported into the
cytosol in the form of PCr (Dolder et al., 2003).
The active ATP/ADP exchange maintained by coupled MtCK enhances ATP production
by the F0F1-ATPases and, therefore, proper functioning of the respiratory chain, which could
otherwise generate elevated superoxide levels other ROS (Schlattner et al., 2013; Wallimann et
al., 2011). The association of MtCK and ANT leads to the saturation of ANT with ADP,
enhancing the transport back of ADP into the matrix to be recharged by the F0F1-ATPase,
efficiently couples substrate oxidation to ATP production (Vendelin et al., 2004). Therefore, the
tight coupling avoids futile electron transfer and might lower ROS production (Wallimann et al.,
2011). Positively, the mitochondrial respiration in the presence of Cr needs only a low level of
ADP to be fully stimulated, whereas in the absence of Cr comparably high level of ADP is
needed for a similar respiratory rate (Kay et al., 2000; Saks et al., 2000). This significant
phenomenon is called creatine-stimulated respiration, which is entirely dependent on the
presence of MtCK (Wallimann et al., 2011).

19

The unique cube-like octameric structures of MtCK maintain multiple interactions with
the mitochondrial membranes' phospholipids (Eder et al., 2000; Fritz-Wolf et al., 1996; Maniti et
al., 2009; Wallimann et al., 2011). The capability of MtCK to bind to and cross-link between
inner and outer mitochondrial membranes enhances the mechanical stabilization of mitochondria
(Speer et al., 2005) and facilitates lipid exchange between the two membranes (Epand, Schlattner
et al., 2007). The MtCK is involved in the mitochondrial permeability transition (MPT) pore
complex (Dolder et al., 2003; O’Gorman et al., 1997). The MPT is a transmembrane protein
residing in the mitochondrial inner membrane, which is typically closed, and it opens when
stimulated by mitochondrial matrix Ca2+ accumulation, adenine nucleotide depletion, increased
phosphate concentration, or oxidative stress (Bauer & Murphy, 2020; Lemasters et al., 2009).
Opening of the MPT is associated with apoptosis, which often leads to swelling of mitochondria,
rapture, and release of apoptotic factors and eventually causing cell death (Bauer & Murphy,
2020). Studies showed that CK isoforms and Cr had a critical role in maintaining the MPT,
protecting mitochondria, and preventing apoptosis in cells (Brdiczka et al., 2006; Dolder et al.,
2003). Phosphocreatine also binds to mitochondrial membranes and stabilizes them against
swelling (Saks et al., 2000; Schlattner et al., 2013; Wallimann et al., 2011). This suggested the
PCr/CK system was not only protecting the cell by maintaining energetic cellular homeostasis
but also through its antiapoptotic effect.
Creatine, one of the essential elements of the PCr/CK system, is transported into muscle
tissue by a specific CrT (Straumann et al., 2005). The transporter belongs to the SLC6A8 family
of a membrane protein; it is the only known mechanism for Cr uptake across the plasma
membrane and is founded in energy-demanding tissues such as skeletal muscle, heart, kidney,
and brain (Brosnan & Brosnan, 2007; Daly & Seifter, 1980; Fitch & Shields, 1966; Wyss &

20

Kaddurah-Daouk, 2000) The SLC6A8 is a member of the Na+- Cl- dependent manner and it is
classified as a secondary active transporter family, which is related to γ-aminobutyrate, taurine,
and betaine transporters (Colas et al., 2020; Gregor et al., 1995). The gene of CrT is located on
the human X chromosome and encodes for a 635 amino acid, 12 transmembrane domain, protein
with several putative phosphorylation and glycosylation sites (Snow & Murphy, 2001). Creatine
is transported through the plasma membrane by the secondary active transport mechanism which
the transmembrane Na+ gradient powers it with co-transport of two Na+ and one Cl- for each
molecule of Cr (Daly & Seifter, 1980; Guimbal & Kilimann, 1993; Murphy et al., 2001; Odoom
et al., 1996; Snow & Murphy, 2001). There are two isoforms (70 and 55 kDa) in rat skeletal and
cardiac muscle, cerebellum, forebrain, and kidney (Neubauer et al., 1999). Creatine uptake rates
and CrT expression are highest in type I (highly oxidative) skeletal muscle and lowest in type II
(glycolytic) skeletal muscle, whereas CrT mRNA is not significantly different between fiber
types (Murphy et al., 2001).
Creatine’s transport is regulated by various mechanisms that include phosphorylation and
glycosylation of the CrT, and a change in extracellular and intracellular Cr levels would affect Cr
uptake rates through the CrT (Snow & Murphy, 2001; Speer et al., 2004). A creatine transporter
SLC6A8 gene mutation would cause a severe X-linked creatine deficiency syndrome (Molinaro
et al., 2019; Salomons et al., 2003). An X-linked creatine deficiency is an inherited disorder that
primarily affects the brain (Salomons et al., 2003). People with this disorder have intellectual
disability, delayed speech development, behavioral disorders, seizures, slow growth, and exhibit
delayed development of motor skills such as sitting and walking (Anselm et al., 2006; Hahn et
al., 2002; Wang et al., 2018).
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The PCr/CK system involves the pathogenesis of several diseases like cardiovascular and
neurodegenerative diseases (Kitzenberg et al., 2016; Schlattner et al., 2006). The pathogenesis of
those diseases is characterized by mitochondrial dysfunction and production of ROS, which
leads to CK isoforms damage and inactivation, the poor energetic state of the cells, Ca2+
accumulation, and apoptosis (Aksenov et al., 2000; Beal, 2000; Schlattner et al., 2006; Sohal &
Weindruch, 1996; Tarnopolsky & Beal, 2001; Thomas et al., 1994). In 1939, a study showed that
the impairment of CK enzymes involved the pathogenesis of heart failure disease (Kitzenberg et
al., 2016). The reduction of Cr also involved heart failure pathogenesis due to the
downregulation of CrT (Neubauer, 2007; Neubauer et al., 1999; Shen et al., 2005). Several
studies also showed that dilated cardiomyopathy patients have a reduced myocardial PCr/ATP
ratio associated with the severity of symptoms and a higher mortality rate (Neubauer et al., 1997;
Zervou et al., 2015). An animal model study showed a reduced inotropic reserve and increased
susceptibility to ischemia associated with PCr/Cr deficiency in transgenic mice unable to
synthesize Cr (ten Hove et al., 2005). In acute coronary artery diseases (CAD), there is an
immediate energy crisis with insufficient oxygen to support ATP production via OP. Within
minutes, PCr and ATP levels are rapidly depleted, leading to stop cardiac muscle contraction
(Zervou et al., 2015).
Inactivation of CK isoforms mainly affects work performance and Ca2+ homeostasis
(Steeghs et al., 1997). Impairment of the PCr/CK system causes energy depletion and reduction
in PCr and ATP leading to impairment of SERCA, which induces Ca2+ accumulation, more ROS
generation, and apoptosis, therefore, entering a vicious cycle with progressive inactivation of CK
isoforms (de Groof et al., 2002; Hamman et al., 1995; Minajeva et al., 1996; Rossi et al., 1990;
Soboll et al., 1999; Steeghs et al., 1997). A preclinical study showed CK overexpression in the
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heart failure mice model significantly increases ATP synthesis, enhances systolic function and
cardiac output, and improves survival rate (Gupta et al., 2012). Therefore, the prevention
impairment of CK isoforms and decline of total Cr might have a significant therapeutic role in
those diseases through a nutritional supplement intervention (Neubauer, 2007).
Doxorubicin
In 1974, the U.S. Food and Drug Administration approved the anticancer drug Dox,
which had been isolated for the first time from Streptomyces peucetius early in the 1960s
(Carvalho et al., 2009; Weiss et al., 1986). Doxorubicin is an anthracycline antibiotic
chemotherapy and is one of the most potent antineoplastic drugs prescribed in the treatment of
several cancers including breast, lung, gastric, ovarian, thyroid, lymphoma, multiple myeloma,
sarcoma, and pediatric cancers (Cortés-Funes & Coronado, 2007; Thorn et al., 2011; Weiss,
1992; Weiss et al., 1986). All anthracyclines have a quinone-containing rigid planar aromatic
ring structure bound by a glycosidic bond to an amino sugar, daunosamine, which has substantial
clinical importance (Minotti et al., 2004). Doxorubicin differs from other anthracyclines only by
the presence of a C-14 hydroxyl group (Carvalho et al., 2009; Cortés-Funes & Coronado, 2007).
Although the exact mechanism of action of anthracyclines has not been well-defined, in
1984, the anthracyclines' mechanism was described for the first time (Cortés-Funes & Coronado,
2007). Doxorubicin halts the cell cycle, damages DNA, and prevents tumor cells' growth through
two main mechanisms. The first mechanism is DNA intercalation where Dox induces inhibition
of topoisomerase IIα, causing accumulation of protein-linked double and single-strand DNA
breaks, which eventually lead to cytotoxic DNA damage and prevention of DNA replication and
cell death (Hortobágyi, 1997; Zunino & Capranico, 1990). This mechanism occurs when Dox
diffuses into the tumor cell and binds the proteosome's 20S subunit, forming a doxorubicin
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proteasome complex, which enters the nucleus through the nuclear pore complexes. Doxorubicin
then dissociates itself from the proteasome and binds to the DNA (Hilmer et al., 2004). One
study also showed that Dox could intercalate mitochondrial DNA (Ashley & Poulton, 2009).
The second mechanism, Dox accumulation, causes ROS generation in the tumor cell,
which causes plasma membranes, DNA, and protein damage (Gewirtz, 1999; Thorn et al., 2011).
Doxorubicin-induced hydrogen peroxide and hydroxyl radical production might cause lipid
peroxidation, membrane damage, DNA damage, oxidative stress and triggers apoptotic cell death
pathways (Doroshow, 1986). In the mitochondria of a tumor cell, Dox accumulation leads to a
redox cycling at complex I of the mitochondrial respiratory chain, where single electrons are
transferred to the quinone structure of Dox mediated by cytochrome P450 reductase,
nicotinamide adenine dinucleotide dehydrogenase, and xanthine oxidase, which finally interact
with oxygen to form superoxide, hydroxyl radicals, and peroxides (Bachur et al., 1978; Bates &
Winterbourn, 1982; Benchekroun et al., 1993; Berlin & Haseltine, 1981; Doroshow, 1983;
Goodman & Hochstein, 1977; Graham et al., 1987; Sinha, 1989). The accumulation of
superoxide, hydroxyl radicals, and peroxides induces apoptotic pathways by activation caspase 9,
caspase 3, and cytochrome C release into the cytosol causing cell death (Tacar et al., 2013).
Doxorubicin also increases freely intracellular iron, forming a redox cycle with the electron
donors in the mitochondria, which causes superoxide formation at complex Ӏ in the electron
transport chain (Berthiaume & Wallace, 2007; Xu et al., 2005). This interruption of
mitochondrial function might ultimately reduce ATP's availability, which interferes with the
cell's energy-dependent actions and might cause necrosis and cell death (Lebrecht & Walker,
2007). Moreover, Dox binds to cardiolipin, blocking the binding of MtCK to ANT and VDAC,
which might impair the respiratory chain (Tokarska-Schlattner et al., 2007).
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Even though Dox is one of the most effective cytotoxic drugs used in oncology and
improves survival in metastatic breast cancer patients (A’Hern et al., 1993), its use is limited due
to its side effects and toxicities. The side effects include nausea, vomiting, neutropenia, alopecia,
gastrointestinal disturbances, neurologic disturbances, bone marrow aplasia, cardiotoxicity, and
myotoxicity (Carvalho et al., 2009; Hortobágyi, 1997; Hydock et al., 2011; Liu et al., 2006; Shi
et al., 2011; Thorn et al., 2011). Those toxicities harm cancer patients which compromise the
quality of life and impair ADLs and become life-threatening (Brain et al., 2005).
Doxorubicin-Induced Cardiotoxicity
Cardiotoxicity is one of the most severe complications of Dox treatment. In 1973, the
clinical report showed that cancer patients who received more than 550 mg/m2 of Dox treatment
had an increased risk of electrocardiogram changes, impairment of cardiac functions, and heart
failure (Lefrak et al., 1973). The incidence of cardiotoxicity was mainly dependent on Dox dose
with an incidence of around 4% with a cumulative Dox dose of 500–550 mg/m2, 18% with a Dox
dose of 551–600 mg/m2, and 36% when the dose exceeded 600 mg/m2 (Chatterjee et al., 2010;
Kim, Kim et al., 2003; Shi et al., 2011). Acute and chronic toxicities are manifestations of Doxinduced cardiotoxicity. The incidence of acute cardiac toxicity in patients is about 11% and
might occur within three days of Dox treatment (Chatterjee et al., 2010; Takemura & Fujiwara,
2007). In clinical studies, chest pain, palpitations, hypotension, low ejection fraction, and altered
diastolic function and electrocardiogram changes were common symptoms of acute
cardiotoxicity due to myopericarditis and arrhythmia (Chatterjee et al., 2010; Haq et al., 1985;
Singal et al., 1987; Swain et al., 2003; Takemura & Fujiwara, 2007). After 20 minutes of
receiving 1.5 mg/kg of Dox treatment, cardiac output and left ventricular peak systolic pressure
decreased in an animal model study (Ditchey et al., 1984). Moreover, in an in vivo study, the

25

deterioration of left ventricle function correlated with dose after five days of receiving Dox in
rats (Hydock et al., 2011). The cardiac mass reduction was also correlated with Dox dose, which
may contribute to chronic cardiotoxicity (Hydock et al., 2011). The mechanisms for these acute
changes are not well known but might due to Dox-induced myocardial edema, which is
reversible (Chatterjee et al., 2010; Singal et al., 1987; Swain et al., 2003).
Chronic cardiotoxicity increases with cumulative Dox doses (Kim et al., 2018), which
causes progressive myocardial damage and dilated cardiomyopathy and might cause congestive
heart failure (CHF; Chatterjee et al., 2010; Shi et al., 2011; Swain et al., 2003). The incidence of
chronic Dox-induced cardiotoxicity is about 1.7% and is usually seen within one month of
receiving the last Dox dose but might occur even after 10 years (Chatterjee et al., 2010; von Hoff
et al., 1979). The incidence of doxorubicin cardiomyopathy and CHF is primarily related to Dox
dose (Chatterjee et al., 2010). Congestive heart failure clinical manifestation and symptoms
include low ejection fraction, low cardiac output, shortness of breath, drowsiness, lack of energy,
and generalized pain, which leads to compromised quality of life of patients (Blinderman et al.,
2008). In animal studies, Dox reduced left ventricle developed pressure, ejection fraction, and
increased end-diastolic pressure (Hayward & Hydock, 2007; Hydock et al., 2008; Singal et al.,
2000). A preclinical study also showed that dogs receiving several doses of Dox had a
progressive reduction in systolic function, diastolic functions, cardiac index, and an increase in
left ventricular end-diastolic pressure (Unverferth et al., 1985). The higher the Dox dose, the
higher reduction in left ventricular function (Hayward & Hydock, 2007). The microscopic
histological features of Dox-induced cardiotoxicity were myofibrillar loss, cytoplasmic
vacuolization, apoptosis, interstitial edema, and fibroplasia (Billingham et al., 1978; Buja et al.,
1973; Shi et al., 2011; Takemura & Fujiwara, 2007).
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While Dox-induced cardiotoxicity's exact mechanisms are not entirely understood, they
seem to be multifactorial processes that lead to cardiomyocyte death (Kalyanaraman et al., 2002;
Minotti et al., 2004). It also seems that therapeutic and toxicity responses to Dox treatment are
overlapping and they share oxidative stress and apoptosis. Several reports confirmed that
increased oxidative stress with increased labile intracellular iron and ROS generation due to Dox
treatment had been considered the classical mechanism of cardiotoxicity (Chatterjee et al., 2010;
Shi et al., 2011; Takemura & Fujiwara, 2007). The increased generation of ROS by Dox
treatment is one of the main mechanisms to eradicate tumor cells, but it also negatively impacts
healthy tissue, leading to cardiotoxicity and myotoxicity (Shi et al., 2011). An increase in
oxidative stress with the release of ROS causes lipid peroxidation, protein carbonyl formation,
activation of the ubiquitin-proteasome system, increased proteolysis, apoptosis, autophagy, and
nuclear DNA damage, which eventuates to impaired cardiac function (Chatterjee et al., 2010; Shi
et al., 2011; Singal et al., 2000). Several studies also reported that Dox treatment leads to the
downregulation of gene expression of cardiac α-actin, myosin light and heavy chains, troponin-I,
and desmin proteins (Aries et al., 2004; Kim, Ma et al., 2003; Lou et al., 2005). Despite the
commonly accepted ROS and iron theory as the primary mechanism of Dox-induced
cardiotoxicity, an antioxidant treatment failed to attenuate toxicity induced by Dox treatment
(Shi et al., 2011). Moreover, studies with potent and selective chelators for iron showed negative
or mixed results, suggesting ROS and iron were not the only mechanisms involved in Doxinduced cardiotoxicity (Simůnek et al., 2009).
An alteration in energy metabolism also seems to be a central mechanism of Dox-induced
cardiotoxicity. The ATP's source in cardiac muscle is mainly from the mitochondria, which
produces about 90% of the ATP utilized by cardiomyocytes (Ventura-Clapier et al., 2004).
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Therefore, any impairment of mitochondrial function would likely affect the cellular energy
homeostasis in cardiomyocytes. Several studies showed Dox treatment decreased ATP
production, PCr, and PCr/ATP ratio in cardiac muscle (Azuma et al., 1981; Eidenschink et al.,
2000; Nicolay & de Kruijff, 1987; Ohhara et al., 1981; Pelikan et al., 1986; Sayed-Ahmed et al.,
2000; Seraydarian et al., 1977; Shneyvays et al., 2001; Tokarska-Schlattner, Zaugg et al., 2006;
Zhou et al., 2001). Doxorubicin treatment decreases ATP production by different mechanisms;
first, Dox treatment diminishes ATP production from glycolysis by decreasing glucose uptake
and inhibiting PFK (Jeyaseelan et al., 1997; Tokarska-Schlattner, Zaugg et al., 2006). Therefore,
inhibition of PFK might impair the CK-PFK interaction and replenish the PCr pool in the
cytoplasm of cardiomyocytes.
Second, Dox treatment inhibits and down-regulates fatty acid oxidation, which is wellknown as one of the cardiac cells' significant energy sources (Abdel-aleem et al., 1997; Bordoni
et al., 1999; Sayed-Ahmed et al., 1999, 2000; Tokarska-Schlattner, Wallimann et al., 2006). An
impairment of fatty acid oxidation is one manifestation of mitochondria dysfunction, which
modifies mitochondria's energy-coupling properties (Tokarska-Schlattner, Wallimann et al.,
2006; Tokarska-Schlattner, Zaugg, 2006). Third, Dox treatment inhibits the respiratory chain,
OP, and inactivate mitochondrial F0F1-ATPase, which cause low production of mitochondrial
ATP (Bianchi et al., 1987; Cheneval et al., 1983; Marcillat et al., 1989; Muhammed et al., 1983;
Nicolay & de Kruijff, 1987; Tokarska-Schlattner, Zaugg et al., 2006; Wallace, 2003). In
cardiomyocytes, a low ATP availability might negatively affect myofibrillar actomyosin
ATPase, SERCA, Na+/K+-ATPase, and Ca2+ ATPase and leads to impairment of contraction and
relaxation of cardiac muscle and accumulation of Ca2+ (Agteresch et al., 1999; GuimarãesFerreira, 2014; Kitzenberg et al., 2016; Minajeva et al., 1996; Saks, 2008). This might explain

28

low cardiac output and increased left ventricular end-diastolic pressure in cardiomyopathy and
CHF. Low PCr and PCr/ATP ratio in cardiac muscle also might be explained by the inactivation
of CK isoforms by Dox treatment.
Remarkably, Dox treatment not only reduces general ATP production but also causes
impairment of CK isoforms. Several studies showed Dox treatment caused structural damage and
function impairment or inactivation of cardiac CK isoforms (DeAtley et al., 1999; Mihm et al.,
2001; Robison et al., 1989; Tokarska-Schlattner et al., 2002, Tokarska-Schlattner, Wallimann et
al., 2006; Tokarska-Schlattner, Zaugg et al., 2006). Doxorubicin also caused dissociation of
MtCK octamers into dimers and inhibition of MtCK binding to cardiolipin in the mitochondria's
inner membrane (Cheneval et al., 1989; Müller et al., 1985; Tokarska-Schlattner et al., 2002).
Inactivation and dissociation of MtCK octamers into dimers are due to oxidative stress with
increased ROS production by Dox treatment (Tokarska-Schlattner et al., 2002; TokarskaSchlattner, Zaugg et al., 2005, 2006). Oxidative activation of the p-hydroquinone B ring by Dox
treatment is essential for oxidation of sulfhydryl (SH) groups of CK isoforms and this effect
could be prevented by reduced glutathione (Muraoka & Miura, 2004). Doxorubicin has a high
affinity to cardiolipin, which is critical and essential for component mitochondrial structure and
function, energy metabolism, and cardiomyocyte survival (Dudek et al., 2019). Doxorubicincardiolipin binding leads to modified membrane properties and thus changes the function of
several essential mitochondrial membrane proteins like cytochrome c oxidase, inorganic
phosphate carrier, and ANT (Beyer & Klingenberg, 1985; Cheneval et al., 1983; Das &
Mazumdar, 2000; Demant, 1991; Goormaghtigh et al., 1982). Studies also showed that mRNA of
the M-CK isoform decreased in cardiac cells treated with Dox treatment (Ito et al., 1990; Torti et
al., 1998), and a CK-M shift isoforms expression with increased B-CK protein (Tokarska-
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Schlattner, Walliman et al., 2006). Impairment of MtCK functions (inactivation, dimerization,
and inhibition of its binding to cardiolipin) not only disturb cellular energy homeostasis in
cardiomyocytes and the shuttle system but also affect the OP, electron transport chain, MPT,
which lead to the initiation of apoptosis and cell death (Schlattner et al., 1998, 2006). Impairment
of the CK-M, functionally coupled to SERCA, would also cause Ca2+ imbalance, interfere with
muscle contraction and relaxation, and Ca2+ accumulation leads to apoptotic cell death (Rossi et
al., 1990; Wallimann et al., 1992).
Interestingly, one study showed Dox treatment inhibited the creatine-stimulated
respiration in isolated mitochondria (Tokarska-Schlattner et al., 2007), leading to an increase in
ROS production and apoptosis. Inhibition of creatine-stimulated respiration might occur due to
the dissociation of MtCK from binding to ANT, VDAC, and cardiolipin and a low influx of ADP
to the matrix F0F1-ATPase (Tokarska-Schlattner et al., 2007). A low concentration of Cr might
also lead to the inhibition of creatine-stimulated respiration in cardiac muscle. One study showed
that subclinical concentration of Dox treatment significantly reduces Vmax of Cr transport and
quantity of CrT at the cell surface of cultured cardiomyocytes (Darrabie et al., 2012). The
damage of CrT by Dox treatment might be due to oxidative damage due to carbonylation or
nitrosylation of sensitive amino acids (Darrabie et al., 2012). Also, an impairment in Cr transport
may compromise the PCr/CK system and energy cell homeostasis in cardiac muscle (Darrabie et
al., 2012; Tokarska-Schlattner et al., 2007). Creatine and CrT might signify a target for early
therapeutic intervention to mitigate Dox-induced cardiotoxicity by preserving the PCr/CK
system.
The cardiotoxicity induced by Dox treatment compromises cancer patients' quality of life
by potentially inducing cardiomyopathy and CHF but it might indirectly also cause myotoxicity
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(Hydock et al., 2011). Skeletal muscle dysfunction is associated with Dox-induced cardiotoxicity
(Hydock et al., 2011). With Dox-induced cardiomyopathy and CHF, low cardiac output and
reduced blood flow contribute to the development of Dox-induced myotoxicity (Harrington &
Coats, 1997; Harrington et al., 1997; Hydock et al., 2011; Libera et al., 2008; Nakamura et al.,
1995). Moreover, the altered cardiovascular dynamics could also lead to physiological changes
within the skeletal muscles (Hydock et al., 2011) including metabolic changes of skeletal muscle
and muscle fibers shifting into more anaerobic types (Zizola & Schulze, 2013). A sedentary
lifestyle of cancer patients and insufficient energy consumption might also be factors that could
further alter skeletal muscle characteristics (Adamsen et al., 2009; Inui, 2002).
Doxorubicin-Induced Myotoxicity
A manifestation of Dox-induced myotoxicity includes fatigue, cachexia, and skeletal
muscle dysfunction (Bredahl et al., 2016; Hiensch et al., 2019; Hydock et al., 2011; van Norren
et al., 2009). In a clinical study, increased fatigue occurred after one to two courses of Dox in
children and adolescents with cancer (Hockenberry et al., 2009). Several clinical studies showed
a decline in functional capacity and a rapid increase in fatigue in breast cancer, lymphoma, and
leukemia patients who received Dox treatment (Elbl et al., 2006; Gilliam & Clair, 2011; Villani
et al., 2009). A preclinical study showed ex vivo skeletal muscle function of rats receiving
different doses of Dox (10 mg/kg, 12.5 mg/kg, and 15 mg/kg) had different results related to Dox
treatment dose (Hydock et al., 2011). Maximal twitch force was the lowest at 15 mg/kg of Dox
and Dox-induced fatigue was profound in soleus (SOL) muscle (Hydock et al., 2011). Fatigue
was one of the most common distressing and persistent symptoms that compromised cancer
patients' quality of life (Gilliam & Clair, 2011; Wang & Woodruff, 2015).
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Cancer cachexia is a severe and multifactorial syndrome characterized by systemic
inflammation, negative protein and energy balance, and involuntary loss of lean body mass with
or without wasting adipose tissue (Fearon et al., 2011). The pathophysiology of cancer cachexia
is driven by a variable combination of anorexia and abnormal metabolism. Cytokines like tumor
necrosis factor–α (TNF-α), interleukin‐1, interleukin‐6, and interferon‐γ play a critical role in
cachexia, which decrease protein synthesis, increase protein degradation, increase lipolysis,
suppress lipoprotein‐lipase in adipose tissue, increase hepatic protein production, increase
gluconeogenesis, and cause insulin resistance (Esper & Harb, 2005; Nicolini et al., 2013;
Peterson & Mozer, 2017). Cancer cachexia has a poor prognosis and is associated with a high
mortality rate (Hulmi et al., 2018; Kazemi-Bajestani et al., 2016). Doxorubicin might play a role
in the onset of cachexia or muscle wasting, affecting 50–80% of cancer patients and accounting
for approximately 20% of cancer-related deaths (Argilés et al., 2014; Hiensch et al., 2019;
Vaughan et al., 2013). A recent meta-analysis showed Dox treatment caused skeletal muscle
atrophy with reduced skeletal muscle mass and muscle strength in preclinical models (Hiensch et
al., 2019). Similarly, non-small cell lung cancer patients receiving a chemotherapy regime with
Dox showed decreased body weight and muscle mass (Tozer et al., 2008). Additionally, after
receiving Dox, skeletal muscle biopsies from patients with sarcoma or melanoma showed
reduced size in type I and type II fibers (Bonifati et al., 2000). An experimental study in dogs
also showed that skeletal muscle atrophy and weakness correlated with a high Dox level in the
quadriceps muscle (Pfeiffer et al., 1997).
Skeletal muscle dysfunction induced by Dox treatment included a reduction in maximal
twitch force, rate of force development, rate of force decline, and increased fatigue (De Beer et
al., 1992; Ertunc et al., 2009; Hydock et al., 2011; van Norren et al., 2009). Doxorubicin
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injection into the orbicularis oculi muscle caused myofibrillar dissolution within five minutes
(McLoon et al., 1993). Multiple-dose Dox treatment caused a decrease in grip strength and an
increase in fatigue index in rats (Park et al., 2019). A preclinical study showed one dose of Dox
(20 mg/kg) altered the contractile function and decreased maximal absolute force in skeletal
muscles (Gilliam et al., 2009). One study also showed Dox treatment resulted in reduced body
mass and impaired skeletal muscle function was dose-dependent and related to cardiac function
(Hydock et al., 2011).
Further, Dox treatment exerts a negative effect on the diaphragm (DIA) and respiratory
muscles. A case report study showed that after receiving a chemotherapy regime with Dox,
lymphoma patients were admitted to the hospital with acute dyspnea, low oxygen saturation, and
decreased inspiratory and expiratory pressures due to bilateral DIA weakness (Stevens & Sporn,
2014). In preclinical studies, Dox treatment decreased DIA force production and stimulated
inflammation due to muscle fiber injury (Gilliam, Moylan, Callahan et al., 2011; Gilliam,
Moylan, Ferreira et al., 2011). Dyspnea is a devastating symptom with fatigue among advanced
cancer patients, which might be due to cancer disease itself, Dox-induced cardiotoxicity, or
possible Dox direct effect on DIA (Blinderman et al., 2008; Ripamonti, 1999; Stevens & Sporn,
2014).
Even though the main mechanisms causing Dox-induced myotoxicity are not entirely
understood, several studies have shown Dox treatment increased ROS generation similar to the
cardiac muscle (Gilliam & Clair, 2011). Doxorubicin could directly enhance oxidants by
disrupting the mitochondrial electron transport chain, undergoing redox cycling, and decreasing
cellular antioxidant defenses (Wang et al., 2004; Zhao et al., 2010). Indirectly, Dox could
increase ROS by stimulating an inflammatory factor TNF-α (Gilliam & Clair, 2011; Gilliam,
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Moylan, Ferreira et al., 2011; Hiensch et al., 2019). Tumor necrosis factor-alpha is a cytokine
produced by numerous cell types including cardiac and skeletal myocytes, elevated in cancer,
with chemotherapy exacerbating this response (Bower et al., 2002). Doxorubicin through TNF-α
receptor subtype 1 increases TNF-α in skeletal and cardiac muscles, leading to increased ROS
(Hardin et al., 2008; Mariappan et al., 2007). Both ROS and TNF-α mediators could lead to the
adverse effects of Dox on skeletal muscle function. An increase in ROS stimulates apoptosis,
autophagy, activation of the ubiquitin‐proteasome pathway (UPP), and disturbing Ca2+
homeostasis (Gilliam & Clair, 2011; Hiensch et al., 2019).
Doxorubicin‐mediated mitochondrial ROS production can promote apoptosis by
increasing calpain‐1, caspase‐3, and caspase-9 (Min et al., 2015). Calpains and caspases are
proteases that could promote muscle catabolism and atrophy by cleaving structural proteins and
degrading intact myofibrillar proteins (Primeau et al., 2002; Smuder et al., 2011b). Similarly,
Dox treatment promotes apoptosis by increasing Bax and apoptotic DNA fragmentation in aged
mouse skeletal muscle (Sin et al., 2016; Yu et al., 2014). One study also showed Dox-mediated
mitochondrial ROS production degraded myosin, actin, troponin I, and α‐actinin through
proteases (Smuder et al., 2011b). Doxorubicin treatment might also induce myonuclear DNA
damage with subsequent calpains and caspases activation leading to apoptosis (Hiensch et al.,
2019). The mechanisms of Dox-induced skeletal muscle dysfunction and Dox-induced cachexia
and atrophy might occur due to promote apoptosis by proteases.
Several studies showed Dox induced autophagy through the upregulation of several
proteins in the autophagic signaling pathway that could promote increased protein breakdown
and upregulated autophagy activity could induce apoptosis‐mediated cell death (Hiensch et al.,
2019; Wani et al., 2015). Doxorubicin increased autophagy markers (Atg12 mRNA, Atg12

34

protein, and Atg12-Atg5 complex) in skeletal muscle (Hiensch et al., 2019; Smuder et al.,
2011c). Doxorubicin treatment increased transcription of BNIP3 in SOL muscle, which is the
FoxO target gene that induces autophagy, promoting mitochondrial dysfunction and apoptosis
(Kavazis et al., 2014). This suggested Dox-induced autophagy led to protein degradation and cell
death.
Increased muscle protein degradation and proteolysis occur typically through activation
of the UPP (Lecker et al., 2006). Interestingly, one study showed Dox treatment increased the
transcription of select FoxO target genes, which involved the UPP by increasing transcription of
atrophy‐related genes atrogin‐1/MaFbx and MuRF‐1 (Kavazis et al., 2014). The same study also
showed Dox treatment increased myostatin mRNA and atrogin‐1/MaFbx expressions that inhibit
muscle growth through FoxO activation (Kavazis et al., 2014). Another study showed Dox
treatment increased E3 ubiquitin ligase atrogin‐1 mRNA, a rate‐limiting step in the UPP (Hulmi
et al., 2018).
Several studies reported that Dox treatment might alter Ca2+ homeostasis through
impaired intracellular Ca2+ release and uptake mechanisms by reducing sarcolemmadihydropyridine- sensitive Ca2+ channel activity, decreasing specific isoforms of SERCA, and
increasing Ca2+ release by ryanodine receptors at the SR (Abramson et al., 1988; Arai et al.,
2000; Ertunc et al., 2009; Periasamy & Kalyanasundaram, 2007; Tarpey et al., 2019; Zorzato et
al., 1985). It is well-known that Ca2+ homeostasis plays a significant role in regulating skeletal
muscle contraction and relaxation and, therefore, impairment in Ca2+ homeostasis helps explain
one element of Dox-induced skeletal muscle dysfunction (Szent-Györgyi, 1975; Wakabayashi,
2015). Doxorubicin inhibits Ca2+ uptake through SERCA, which results in a transient Ca2+
increase in the cytosol (Abramson et al., 1988; De Beer et al., 1992; Ertunc et al., 2009; Tarpey
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et al., 2019; van Norren et al., 2009). The mechanism of SERCA inhibition may be due to the
oxidation of thiol groups by ROS (Hanna et al., 2014; Tarpey et al., 2019). There was agreement
that Dox could disturb skeletal muscle function but the primary mechanism by which this
occurred is still vague. Doxorubicin affects the mitochondrial respiratory chain and OP, which
increases ROS formation and leads to altered energy availability and altered cellular function
(Smuder et al., 2011a; van Norren et al., 2009). Additionally, deterioration of energy stores of
PCr and ATP leads to increased intracellular free Ca2+ and reduced energy availability for
cellular functions (Honda et al., 2004). The oxidative stress and ROS induced by Dox leads to
lipid oxidation of membranes and the oxidation of Ca2+ handling proteins (SERCA and
ryanodine receptors). Doxorubicin also inhibits SERCA gene transcription in cardiac muscle
(Arai et al., 2000).
An impairment in cellar energetic homeostasis might be one of the mechanisms of Doxinduced myotoxicity. Doxorubicin decreases Cr, CK isoforms, and CrT; impairs proper coupling
of mitochondrially-produced ATP to the replenish of PCr; and reduces ATP production in
cardiac muscle, which leads to cell energy homeostasis and energy metabolism impairments
(Chaudhari et al., 2017; Darrabie et al., 2012; Tokarska-Schlattner, Wallimann et al., 2006;
Tokarska-Schlattner, Zaugg et al., 2006). In addition, Dox‐induced skeletal muscle
mitochondriopathy with the generation of ROS and OP inhibition might lead to decreased ATP
production (Tarpey et al., 2019). A recent study showed a weekly dose of Dox (12 mg/kg) for
four weeks significantly decreased CK-M in the SOL muscle (Bredahl, Sharif et al., 2020). This
suggested CK isoforms have a significant role in the pathogenesis of skeletal muscle dysfunction
induced by Dox. Due to the negative impact of Dox on skeletal muscles in cancer patients, there
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is now a push to explore and understand the role of CK isoforms and CrT in Dox-induced
myotoxicity.
Doxorubicin treatment is associated with toxicities that could affect several body
systems. These toxicities might contribute to CHF, fatigue, and a decline in functional
capabilities, which could compromise cancer patients' quality of life. Due to the negative impact
of Dox on cancer patients, there is now a push to explore non-pharmacological therapeutic
interventions that could alleviate Dox-induced cytotoxicity. Interventions to minimize Doxinduced cytotoxicity are crucial and approaches showing promise include exercise and
nutritional supplement interventions.
Exercise and Doxorubicin
Physical activity and exercise are well-known to reduce the risk for chronic diseases (e.g.,
obesity, cardiovascular disease, diabetes, cancer, and stroke) and mortality while providing a
means for primary disease prevention (Anderson & Durstine, 2019). Current literature
showcased strong evidence that exercise decreases the risk of colon, breast, kidney,
endometrium, bladder, stomach, and esophageal cancers (Patel et al., 2019). Several clinical
studies also showed exercise during and after treatment enhanced physical and psychological
function, minimized cancer-related fatigue, and improved cancer patients' quality of life
(Gerritsen & Vincent, 2016; Quist et al., 2006; Spence et al., 2010). Moreover, exercise is safe
and effective during chemotherapy administration (Campbell et al., 2019; Cheema et al., 2008;
Jones & Demark-Wahnefried, 2006; Meneses-Echávez et al., 2015; Schmidt et al., 2015; Van
Moll et al., 2016).
Numerous preclinical studies showed aerobic exercise before Dox treatment preserved
cardiac function, improved left ventricular pressures, and attenuated Dox-induced cardiotoxicity
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(Chicco et al., 2005, 2006; Hydock et al., 2008; Wonders et al., 2008). Aerobic exercise also
attenuated cardiac mitochondria damage, increased superoxide dismutase activity, and prevented
cardiorespiratory dysfunction in rats receiving Dox (Ascensão et al., 2011; Morton et al., 2019).
In myotoxicity induced by Dox, aerobic exercise attenuated deterioration of mitochondria
function and apoptosis, preventing muscle weakness and central fatigue (Park et al., 2019).
Several studies also showed exercise might protect against oxidative stress proteolysis,
autophagy, and myopathy and preserve skeletal muscle function in animals receiving Dox
treatment (Bredahl et al., 2016; Kavazis et al., 2014; Smuder et al., 2011a, 2011b). Equally,
resistance exercise before and during Dox administration preserved extensor digitorum longus
(EDL) muscle mass and attenuated the decline of CK-M expression in SOL muscle and skeletal
muscle function in rats (Bredahl, Sharif et al., 2020). These data suggested exercise mitigated
Dox-induced cytotoxicity in cardiac and skeletal muscles.
Nevertheless, exercise interventions could be challenging because exercise adherence is
typically low in cancer patients undergoing treatment and in patients who recently completed
treatment (Courneya et al., 2007; Furmaniak et al., 2016). Additionally, one study reported only
30-40% of newly diagnosed cancer patients met the minimum recommendations for physical
activity, making exercise interventions more challenging following diagnosis (Iyer et al., 2016).
This led to the exploration of non-exercise interventions to alleviate Dox-induced cytotoxicity
that could have a high adherence rate in cancer patients receiving Dox. Supplementing the diet
with creatine as a non-pharmacological therapeutic intervention to alleviate Dox-induced
cytotoxicity is one possible intervention.
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Creatine and Creatine Metabolism
In 1832, for the first time, French scientist Michel Eugene Chevreul successfully
extracted Cr from red meat and creatine is a Greek word meaning flesh (Balsom et al., 1994).
Over 95% of Cr is found in the skeletal muscles and the remaining Cr pool is located in the
brain, liver, kidney, and testes (Walker, 1979). Total Cr consists of two-thirds of PCr and onethird free Cr, which averages about 120 mmol/kg of dry muscle mass for a 70 kg individual
(Hultman et al., 1996). In most people, the upper limit of Cr storage is about 160 mmol/kg of dry
muscle mass (Green et al., 1996; Hultman et al., 1996). The amount of total Cr is dependent on
skeletal muscle fiber type where type II muscle fibers have a higher level of Cr and PCr (Casey
et al., 1996; Persky & Brazeau, 2001). Creatine uptake also varies among muscle fibers where
type II muscle fibers have a higher Km and Vmax than type I muscle fibers, which suggests
intracellular Cr levels play a role in regulating the skeletal muscle Cr uptake. (Kushmerick et al.,
1992; Willott et al., 1999).
Intramuscular Cr can be degraded into a metabolic byproduct creatinine and excreted in
the urine and, therefore, the human body needs to replenish approximately 1-3 g of Cr per day to
preserve typical Cr stores depending on muscle mass. (Balsom et al., 1994; Harris et al., 1992;
Hultman et al., 1996; Wyss & Kaddurah-Daouk, 2000). About half of the daily need for Cr is
obtained from the diet (fish and meat), and the remaining amount of Cr is synthesized in the liver
and kidneys (Balsom et al., 1994; Brosnan & Brosnan, 2016). The endogenous synthesis of Cr is
decreased with Cr supplementation, although the endogenous synthesis returns to baseline after
supplementation is stopped (Cooper et al., 2012; Walker, 1979)
Creatine, a nitrogenous amine (N-(aminoiminomethyl)-N-methyl glycine), is synthesized
from arginine, glycine, and methionine (Balsom et al., 1994; Cooper et al., 2012). In the kidney,
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the amidino group is transferred from arginine to glycine, yielding L-ornithine and
guanidinoacetic acid (GAA), catalyzed by L-arginine: glycine amindinotransferase (AGAT). The
product is then transferred to the liver where guanidinoacetate N-methyltransferase (GAMT)
methylates GAA using S-adenosyl methionine to form Cr (Brosnan & Brosnan, 2016; Walker,
1979; Wyss & Kaddurah-Daouk, 2000). After that, Cr circulates in the blood and transports into
the tissue by CrT (Murphy et al., 2001). Creatine uptake is enhanced by thyroid hormone,
insulin-like growth factor, catecholamines, and exercise (Hall & Trojian, 2013; Harris et al.,
1992; Robinson et al., 1999). In muscles, Cr is phosphorylated to form PCr in a reversible
enzymatic reaction facilitated by CK and involves the PCr/CK system and ATP homeostasis as
described before.
Creatine Supplementation
For the first time in the early 20th century, Denis and Folin discovered that Cr
supplementation increased intramuscular Cr stores (Demant & Rhodes, 1999). Since the early
1990s, Cr supplementation has become one of the most popular nutritional ergogenic aids for
athletes to enhance resistance training (Demant & Rhodes, 1999). Creatine monohydrate is the
most extensively studied and clinically effective form of Cr for nutritional supplements in terms
of muscle uptake and increased high-intensity exercise capacity (Jäger et al., 2011; Kreider et al.,
2017). Numerous studies showed intramuscular stores of total Cr and PC increased by ingestion
Cr monohydrate for five to seven days with a dose of 20-25 g per day (Burke et al., 2003; Casey
et al., 1996; Greenhaff et al., 1994; Harris et al., 1992; Hultman et al., 1996; Kreider et al.,
2017). The highest increase of Cr and PCr was showed to be in the first two days of
supplementation (Harris et al., 1992). The typical dose of Cr supplementation to increase
strength performance includes both a loading and maintenance phase. In the loading phase, a

40

person ingests 20 g of Cr monohydrate per day for five to seven days (0.3 g per Kg of the body
mass), and in the maintenance phase, a person can ingest 3-5 g per day (0.03 g per Kg of the
body mass), where the length of the maintenance phase is from 28 days to 10 weeks (Harris et
al., 1992; Hultman et al., 1996). Muscle Cr levels do not decrease below baseline after the stop
of Cr supplementation. Consequently, the potential for long-term suppression of endogenous Cr
synthesis does not appear to occur (Kim et al., 2011; Kreider, 2003). The International Society of
Sports Nutrition (ISSN) recommendations suggested Cr monohydrate is well-tolerated and safe
to consume in healthy untrained and trained people regardless of age (Kreider et al., 2017).
Moreover, position stands by the American Dietetic Association, Dietitians of Canada, and the
American College of Sports Medicine on nutrition for athletic performance have recommended
that Cr monohydrate is the most effective ergogenic nutritional supplement currently available to
athletes in terms of increasing high-intensity exercise capacity and lean body mass during
training (Rodriguez et al., 2009a). Weight gain and water retention were the only consistently
reported side effects from Cr supplementation (Buford et al., 2007; Kreider, 2003; Kreider et al.,
2017).
Several pieces of literature reported that Cr supplementation increased Cr and PCr in
muscles and therefore could enhance acute exercise capacity and training adaptations in
adolescents, younger adults, and older people (Buford et al., 2007; Cornish et al., 2006; Galvan
et al., 2016; Kreider et al., 2017; Tarnopolsky, 2000; Volek et al., 2004). Several studies also
showed Cr supplementation increased performance and muscle strength in short-duration,
maximum-intensity resistance training (Arciero et al., 2001; Becque et al., 2000; Birch et al.,
1994; Casey et al., 1996; Earnest et al., 1995; Hall & Trojian, 2013). The potential ergogenic
benefits of Cr supplementation in athletes included an increase in performance and strength of
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short-duration, maximal-intensity exercises, anaerobic threshold, training tolerance, and muscle
mass (Becque et al., 2000; Butts et al., 2018; Demant & Rhodes, 1999; Kreider et al., 2017;
Volek & Rawson, 2004). Creatine supplementation delays the onset of fatigue and improves
recovery from muscle damage and oxidative stress induced by heavy exercise (Cooper et al.,
2012; Rawson et al., 2011; Santos et al., 2004; Yquel et al., 2002).
The molecular mechanisms of Cr supplementation are not well elucidated. An increase in
intramuscular PCr and Cr is the main benefit of Cr supplementation (Hall & Trojian, 2013).
Creatine supplementation improves muscle performance via enhancing the PCr/CK system,
increasing PCr/ATP ratio, enhancing PCr upsurge availability and resynthesis of ATP between
resistance exercise sets, and facilitating intracellular energy transport (Greenhaff et al., 1993;
Harris et al., 1992; Lemon, 2002; Volek et al., 1999; Wallimann et al., 2011). Glucose
metabolism has also been shown to improve with Cr supplementation, which increases oxidative
enzymes such as MtCK, succinate dehydrogenase, citrate synthase, and glucose transporters
(e.s., GLUT-4), leading to increased glycolytic ATP and replenishment of the PCr pool
(O’Gorman et al., 1996; Ren et al., 1993). It is possible increased levels of PCr might decrease
reliance on anaerobic glycolysis as a replenishment source of ATP and probably mitigate the
formation of lactic acid and enhance performance in high-intensity, more prolonged exercise
tasks approximating 30 to 150 seconds (Williams & Branch, 1998). Clinical studies showed also
tha Cr supplementation increases intramuscular glycogen stores which might increase glycolytic
ATP and enhance muscle performance (Nelson et al., 2001; van Loon et al., 2004). Several
studies also showed that Cr supplementation improves intracellular Ca2+ homeostasis by
enhancing SERCA with increasing Ca2+ uptake by the SR, which leads to shortening of
relaxation time (Bazzucchi et al., 2009; Pulido et al., 1998; van Leemputte et al., 1999). By
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increasing intramuscular Cr and PCr stores and enhancing the PCr shuttle system with Cr
supplementation, the belief is one can increase muscle performance and decrease muscle fatigue.
Evidence also proposed that Cr supplementation might decrease muscle damage and
augment recovery from intense exercise. One study showed Cr supplementation reduced muscle
damage after an acute supramaximal eccentric resistance training session in young males (Cooke
et al., 2009). The authors speculated Cr supplementation before exercise might enhance Ca2+
homeostasis and reduce Ca2+-activated proteases and more influxes of Ca2+ into the muscle.
Creatine supplementation decreased inflammatory markers (CK, prostaglandin E2, TNF-α,
lactate dehydrogenase LDH) in marathon runners (Santos et al., 2004), and inhibited the increase
of TNF-α and C-reactive protein in repeated sprint exercise (Deminice et al., 2013). One study
showed Cr supplementation attenuated the oxidation of DNA and lipid peroxidation induced by a
single bout of resistance exercise (Rahimi, 2011). In addition, in vitro studies demonstrated the
antioxidant effects of Cr to scavenge and decrease ROS generation (Guimarães-Ferreira et al.,
2012; Lawler et al., 2002; Sestili et al., 2006, 2011). Together, these data indicated Cr
supplementation could be an effective strategy to maintain Cr and PCr during a rehabilitation
period after muscle injury and lessen muscle damage induced by a prolonged endurance exercise.
One of Cr supplementation's most special effects is hypertrophy and increased muscle
mass specifically when a resistance exercise program accompanies supplementation. A metaanalysis reported a mean increase in lean body mass of 2.2 kg with Cr supplementation (Branch,
2003). Resistance exercise with Cr supplementation increased muscle fiber diameter by 35%
compared with a 6-15% increase in a placebo group that also completed the resistance exercises
(Volek et al., 1999). Several studies also showed Cr supplementation with resistance exercise
increased muscle mass and cross-sectional area of type II muscle fibers (Becque et al., 2000;
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Burke et al., 2003; Nissen & Sharp, 2003; Vandenberghe et al., 1997; Volek et al., 1999);
however, it seemed Cr supplementation alone without resistance exercise had little effect on
muscle mass. One animal study showed Cr supplementation alone did not increase muscle mass;
however, resistance exercise alone increased muscle mass and this effect was much more
prominent when coupled with Cr supplementation (Ferreira et al., 2005). The hypertrophy
induced by Cr might result from increased protein synthesis or reduced protein degradation
(Persky & Brazeau, 2001). In vitro studies showed exogenous Cr could increase the rate
synthesis of myosin and actin contractile proteins and the degradation rate of the muscle proteins
remained unchanged (Ingwall et al., 1975; Ingwall & Wildenthal, 1976). The mechanism showed
resistance training with Cr supplementation increased expression of both myogenic regulatory
factors (MRFs) mRNA levels and protein of myogenin and MRF-4, stimulating the generation
and regeneration of muscle fibers (Willoughby & Rosene, 2003). Studies also showed Cr
enhances differentiation of myogenic C2C12 cells by increasing the IGF-I mRNA and MRF
mRNA and activating both p38 and Akt/PKB pathways (Deldicque et al., 2007; Louis et al.,
2004). Creatine supplementation, combined with an increased functional load, increases satellite
cell mitotic activity, which might be another hypertrophy mechanism. (Dangott et al., 2000). All
molecular mechanisms of Cr-induced hypertrophy suggested Cr supplementation might have a
role in alleviating cachexia induced by Dox treatment. Creatine supplementation has special
pleiotropic effects on athletes and has potential therapeutic benefits in various diseases.
The Therapeutic Role of Creatine in
Diseases and Disorders
Several researchers have been investigating the potential therapeutic benefits of Cr
supplementation in various clinical populations and animal models of human diseases. Patients
with diseases that result in atrophy or muscle fatigue secondary to impaired energy production

44

may benefit from Cr supplementation. Also, Cr supplementation has a potential benefit in normal
healthy people. Aerobic exercise with Cr supplementation might delay the onset of obesity,
diabetes, and metabolic syndrome (Gualano et al., 2008; Wallimann et al., 2011). An animal
model showed Cr supplementation improved health quality and decreased aging mice's mortality
rate (Bender, Beckers et al., 2008). Substantial evidence supported that Cr supplementation
might improve health status and quality of life in the elderly (Candow & Chilibeck, 2010;
Candow et al., 2015; Gualano et al., 2016; Moon et al., 2013; Rawson & Venezia, 2011).
Particularity, Cr supplementation decreased cholesterol and triglyceride levels, reduced
homocysteine levels and fat accumulation in the liver, and enhanced glycemic control (Deminice
et al., 2015, 2016; Earnest et al., 1996; Gualano et al., 2011; Kreider et al., 1998). A metaanalysis study of 357 elderly showed Cr supplementation with resistance exercise program
increased muscle mass, strength, and functional capacity (Devries & Phillips, 2014).
Creatine supplementation might not only be beneficial for muscle but also for the bone
health of healthy people. Creatine increases bone mineral density in healthy older men and might
prevent osteoporosis in postmenopausal women (Chilibeck et al., 2005; Gerber et al., 2005;
Wallimann et al., 2011). Moreover, Cr supplementation positively affects memory, learning,
mental performance, and cognitive performance (McMorris et al., 2007; Rae et al., 2003). These
data suggest Cr supplementation might play a potential role in preventing diseases and
improving the quality of life in the elderly.
Interestingly, Cr and PCr might play a significant role in maintaining myocardial
bioenergetics during ischemic events (Balestrino et al., 2016). Most clinical intervention studies
of the PCr/CK system during CAD used only PCr (Balestrino et al., 2016) because the PCr is an
active high energy compound of Cr and intravenous administration of PCr better fits in the acute
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clinical setting of myocardial infarction. A clinical trial showed intravenous PCr within six hours
of symptom onset decreased the frequency of ventricular premature beats and the number of
ventricular tachycardia paroxysms in 60 patients with myocardial infarction (Ruda et al., 1988).
Phosphocreatine decreased the release of CK and arrhythmias in acute CAD (Balestrino et al.,
2016). Remarkably, PCr significantly lowered the extent of myocardial necrosis and improved
left ventricular ejection fraction during percutaneous coronary intervention for acute myocardial
infarction (Balestrino et al., 2016). A meta-analysis showed PCr improved spontaneous recovery
of the heart performance after cardiopulmonary bypass and might reduce all-cause short-term
mortality in cardiovascular disease patients undergoing cardiac surgery (Landoni et al., 2016).
Evidence from genetically modified mice unequivocally showed an entire PCr/CK system was
essential for optimal recovery from myocardial ischemia and reperfusion injury (Cao et al.,
2018).
Conversely, one animal study showed Cr supplementation could not increase
intramuscular Cr post-myocardial infarction in rats (Horn et al., 1998). Due to hypoxia-induced
by ischemia, Cr transport in cardiomyocytes was reduced (Santacruz et al., 2017). Creatine
supplementation, however, might have a preventative role against CAD as it decreases risk
factors such as total plasma cholesterol and triglycerides (Earnest et al., 1996). A recent review
article reported that Cr supplementation enhanced vascular health via decreased ROS,
inflammation, and plasma homocysteine with increased Cr stores in endothelial cells, thereby
enhancing endothelial cells and decreasing endothelial cell leakiness (Clarke et al., 2020). This
suggested Cr supplementation might have a preventative therapeutic role in atherosclerosis,
which might lead to hypertension, CAD, and CHF.
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The primary mechanism of PCr to improve cardiac function in acute CAD has not yet
been fully elucidated. Acute ischemia is associated with hypoxia, leading to decreased PCr and
ATP production and negatively impacting cardiac contractility (Zervou et al., 2015). Therefore,
PCr enhances the PCr/CK system and increases ATP's availability at energy consumption sites
including myosin ATPase that provides energy for actomyosin contraction (Wallimann et al.,
2011; Wyss & Kaddurah-Daouk, 2000). Loss of PCr or CK isoforms in the heart results in
contractile dysfunction (Lygate et al., 2013; Neubauer, 2007). Overexpression of CrT protein in
transgenic mice protected against ischemia and reperfusion injury, suggesting Cr and PCr had a
significant role in treating acute CAD (Lygate et al., 2012). Another possible effect of PCr might
be associated with Ca2+ homeostasis; with a high level of PCr and ATP enhancing SERCA,
increasing Ca2+ uptake into SR, and preventing Ca2+ accumulation, which is associated with
apoptosis (Cooke et al., 2009; Wallimann et al., 2011). In addition, binding of PCr to
phospholipid in the plasma membrane enhances membrane stability and protects the membrane
from leakage induced by cell membrane lytic factors (Tokarska-Schlattner et al., 2012),
suggesting PCr might protect cardiomyocytes from cell death and apoptosis.
Regarding heart failure, one study showed Cr supplementation (20 g per day for ten
days) failed to improve ejection fraction but increased strength and endurance exercise
performance (Gordon et al., 1995). Another study also showed Cr supplementation improved
skeletal muscle metabolism by reducing lactate accumulation in CHF patients (Andrews et al.,
1998). Short-term Cr supplementation with standard medication in CHF patients led to increased
body weight and improved muscle strength (Kuethe et al., 2006). Long-term Cr supplementation
in rats with heart failure secondary to myocardial infarction did not increase Cr or PCr or
improve myocardial energy reserve via CK enzymes (Horn et al., 1998). In a heart failure animal
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study, Cr supplementation did not attenuate left ventricular remodeling or prevent the decrease in
total Cr (Horn et al., 1999), which might be due to the downregulation of CrT in cardiac cells
and the low uptake of Cr into cells even with Cr supplementation (Neubauer, 2007; Shen et al.,
2005). Remarkably, Cr supplementation improved muscle metabolism and performance,
suggesting Cr supplementation could improve the ADLs and the quality of life of CHF patients.
Creatine supplementation also has a potential therapeutic role in several other diseases
where a large number of studies explored the short and long-term therapeutic benefits of Cr
supplementation in children and adults with neurodegenerative diseases, cerebrovascular
diseases, and muscular diseases (Balestrino & Adriano, 2019a; Balestrino et al., 2016; Bender,
Samtleben et al., 2008; Dedeoglu et al., 2003; Gualano et al., 2010; Kley et al., 2013; Louis et
al., 2003; Tarnopolsky et al., 2004). These studies provided evidence that Cr supplementation
might improve exercise capacity and clinical outcomes in patients. For example, Gyrate atrophy
is an autosomal recessive disease characterized by chorioretinal degeneration, type II muscle
fibers atrophy, and low muscle Cr and PCr (Ramesh et al., 1991). Creatine supplementation
increased type II muscle fibers size by 45% (Sipilä et al., 1981) and Cr almost normalized low
muscle PCr in Gyrate atrophy patients (Heinänen et al., 1999). Creatine supplementation’s
capability to improve muscular strength and resistance has also been studied in several muscular
degenerative diseases, most notably Duchenne's and other dystrophies. Duchenne muscular
dystrophy is an X-linked progressive myopathy due to mutations within the dystrophin gene and
the only therapy that can slow disease progression is corticosteroids, which are usually
associated with many significant side effects (Koenig et al., 1988; Mendell et al., 1989). One
clinical study showed that eight weeks of Cr supplementation increased muscle strength and
significant improvement in neuromuscular symptom score and daily‐life activities by Medical
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Research Council scales patients with various muscular dystrophies (Walter et al., 2000).
Another study showed five months of Cr supplementation decreased serum CK and lactate
dehydrogenase and improved muscle strength in children with Duchenne muscular dystrophy
(Felber et al., 2000). A double-blind, randomized trial also showed four months of Cr
supplementation increased skeletal muscle mass and handgrip strength and reduced bone
breakdown markers in Duchenne muscular dystrophy (Tarnopolsky et al., 2004).
The molecular mechanisms of the therapeutic role in muscular dystrophy diseases are not
clear yet. However, it might be due to the anabolic effect of Cr by increasing several molecules
like IGF‐1, MRFs, and mechanistic target of rapamycin (mTOR), proliferation and
differentiation of muscle satellite cells, and reduction of ROS generation (Balestrino & Adriano,
2019a; Chilibeck et al., 2017; Kley et al., 2013). An animal model for Duchenne muscular
dystrophy showed that long-term Cr supplementation significantly reduced degeneration and
necrosis, mainly in EDL muscles, and enhanced mitochondrial oxidative capacity and function
(Passaquin et al., 2002). Moreover, one preclinical study showed that incubation of Cr (20 mM)
with mdx myotubes increased PCr level, decreased Ca2+, and increased myotubes' survival rate
and formation (Pulido et al., 1998). This suggested Cr supplementation's critical role was to
improve the cellular energetics of Ca2+ homeostasis by augmentation of SERCA pump activity
and increasing Ca2+ uptake into SR with decreasing cytosolic Ca2+ level and prevention of
apoptosis might be a beneficial effect of Cr. An increase in cytosolic Cr and PCr levels by Cr
supplementation also is likely to stimulate mitochondrial respiration by increasing mitochondrial
ADP levels in the vicinity of the ANT and enhancing MtCK functions, which might play a
critical role in maintaining the MPT, protection of mitochondria, and preventing apoptosis in
cells (Brdiczka et al., 2006; Dolder et al., 2003; Passaquin et al., 2002). Also, the higher level of
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PCr with Cr supplementation increased the binding of PCr to the mitochondrial membrane and
stabilized them against swelling (Saks et al., 2000; Schlattner et al., 2013; Wallimann et al.,
2011).
Remarkably, Cr supplementation may also have a potential therapeutic role in statininduced myopathy (Balestrino & Adriano, 2019a, 2019b). Statins is a 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors drug used to decrease blood
cholesterol levels in patients with a high risk of cardiovascular disease (Valentino et al., 2016).
Statin-induced myopathy is a common side effect characterized by fatigue, pain, tension, muscle
weakness, night cramps, and rhabdomyolysis, which are become worse with exercise (Thompson
et al., 2016). Several studies also reported that statins increased urinary creatine/creatinine ratio
and inhibited GAMT enzyme, leading to decreased intracellular Cr levels (Mangravite et al.,
2013; Phulukdaree et al., 2015; Shewmon & Craig, 2010). A cross‐over, prospective study
showed Cr supplementation prevented statin-induced myopathy with low myopathy score in
patients who had Cr (Shewmon & Craig, 2010). A preclinical study also showed Cr
supplementation prevented mitochondrial distortion and damage by statins by enhancing Ca2+
homeostasis and maintaining the mitochondria (Busanello et al., 2017). These data suggested
that Cr supplementation might also have a potential therapeutic role in preventing Dox-induced
myotoxicity.
Taken together, research has demonstrated that Cr supplementation might have a
potential therapeutic role in cardiovascular diseases, neurodegenerative disease, and
neuromuscular diseases (Balestrino & Adriano, 2019a; Balestrino et al., 2016; Beal, 2011; Curt
et al., 2015; Dedeoglu et al., 2003; Kley et al., 2013; Zervou et al., 2015); might enhance
treatment and might prevent the CAD (Clarke et al., 2020; Earnest et al., 1996; Landoni et al.,
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2016), and improve muscle strength and quality of life in heart failure and Duchenne muscular
dystrophy patients (Balestrino & Adriano, 2019a; Kley et al., 2013; Kuethe et al., 2006; Landoni
et al., 2016; Tarnopolsky et al., 2004).
Creatine and Cancer
Cancer is a syndrome with abnormal cell growth and the second leading cause of death in
the United States (Siegel et al., 2017, 2020). Cancer patients are at a high risk of cachexia and
muscle wasting aggravated by tumor-related factors and cancer therapies (Aversa et al., 2017;
Christensen et al., 2014; Vaughan et al., 2013). Recently, there has been an increasing
appreciation for the role of nutritional and dietary supplement interventions, both alone and with
exercise, to maintain or improve clinically relevant outcomes and augment training adaptations
in cancer patients (Fairman et al., 2019; Gualano et al., 2010; Jatoi et al., 2017).
The role of Cr on cancer has been gradually explored since the PCr/CK system is related
to tumor metabolism through ATP provision (Martin et al., 1994). Several studies reported that
Cr and CK isoforms and activity were decreased in various cancers (Joseph et al., 1997; Onda et
al., 2006; Panigrahy et al., 2006; Tsung, 1983). Creatine, mRNA of CK isoenzymes, and CK
expressions were downregulated in the sarcoma tissue of mice with malignancy progression and
reached deficient levels in the final stage of tumor development (Patra et al., 2008). The same
author reported upregulation of the enzymes involved in Cr synthesis (AGAT and GAMT) and
the enzymes involved in arginine and methionine metabolism (arginase II, ornithinedecarboxylase, S-adenosyl homocysteine hydrolase, and methionine-synthase) in Ehrlich ascites
carcinoma and sarcoma 180 cells, suggesting AGAT and GAMT seemed to be geared to support
cancer cell metabolism in the direction of polyamine and methionine synthesis as both of these
compounds are in high demand in proliferating cancer cells (Patra et al., 2008, 2012).
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The potential anticancer effect of Cr and its analog cyclocreatine has been demonstrated
in different experimental models by inhibiting tumor cell growth (Kornacker et al., 2001; Lillie
et al., 1993; Miller et al., 1993; Wyss & Kaddurah-Daouk, 2000). Various preclinical studies
showed Cr supplementation enhanced the anticancer drug methylglyoxal with or without
ascorbic acid by increasing survival rate, decreasing tumor size, and curing the visible sign of
tumor (Ghosh et al., 2006; Pal et al., 2016; Patra et al., 2012). Creatine supplementation with
methylglyoxal increased CK expression in Ehrlich ascites carcinoma (Patra et al., 2012). The
combination of cyclocreatine and adriamycin also enhanced the inhibition of human prostatic
carcinoma cell proliferation and increased CK activity (Hoosein et al., 1995). One study showed
that 21 days of Cr supplementation attenuated tumor growth and prevented body weight loss
induced by tumor growth in Walker‑256 tumor‑bearing rats (Deminice et al., 2016).
While the molecular mechanisms linking Cr supplementation to cancer biology are yet to
be fully elucidated, one possibility is an increase in Cr level in cancer cells causes inhibition of
glycolysis and generation of acidosis (Kristensen et al., 1999; Miller et al., 1993). Creatine is
also known to have an antioxidant effect (Sestili et al., 2011). A preclinical study showed Cr
supplementation decreased tumor growth, plasma homocysteine, and liver oxidative stress and
prevented body mass loss in Walker-256 tumor-bearing rats (Deminice et al., 2016). Patra et al.
(2012) suggested Cr supplementation might inhibit AGAT and GAMT enzymes and shift the
metabolism pathway away from polyamine and methionine synthesis, which are essential in
cancer cell metabolism. Creatine supplementation enhances methylglyoxal cytotoxicity through
apoptosis in the human breast adenocarcinoma cells (Pal et al., 2016). Interestingly,
methylglyoxal inhibits mitochondrial complex I of cardiac and malignant cells but Cr protects
against this inhibition of cardiac complex I in normal cardiac cells but not in malignant cells (Pal
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et al., 2016; Patra et al., 2012), suggesting Cr supplementation with methylglyoxal enhanced
apoptosis in malignant cells and Cr was not harmful to normal healthy cells.
Recently, one preclinical study showed that Cr supplementation with immunotherapy
produced a significant tumor suppression effect superior to that of each treatment alone (Di Biase
et al., 2019). In particular, checkpoint inhibitor immunotherapy, such as PD-1/PD-L1 blockade
therapies, blocked programmed cell death protein1 (PD-1) on immune cells like T cells that
down-regulated the immune system and promoted self-tolerance by suppressing T cell
inflammatory activity when interacting with PD-L1 on cancer cells (Zou et al., 2016). Blocking
the PD-1-PD-L1 interaction might allow the cytotoxic CD8 T cells to attack the tumor. The same
study showed that supplementation suppressed tumor growth with a significant reduction of PD1 among cytotoxic CD8 T cells (Di Biase et al., 2019). In CrT knockout mice model, the study
showed Cr uptake deficiency severely impaired immunity, mainly in T cells, suggesting Cr
supplementation played a critical role in cytotoxic CD8 T cell metabolism (Di Biase et al., 2019).
The molecular mechanisms of Cr supplementation are not well understood yet but it was
reported that T cells expressed a low level of AGAT and GAMT enzymes with low de novo Cr
synthesis that T cells profoundly rely on taking Cr by CrT from extracellular sources (Di Biase et
al., 2019). Therefore, Cr supplementation enhanced the PCr/CK system's performance with a
high ATP level through upregulation of CrT and CK expression (Di Biase et al., 2019).
Taken together, it has been established that Cr supplementation has a significant
therapeutic role in cancer where it inhibits the growth of tumor cells, enhances anticancer
therapy, and improves immune cells to attack the tumor (Deminice et al., 2016; Di Biase et al.,
2019; Pal et al., 2016; Patra et al., 2012; Wyss & Kaddurah-Daouk, 2000). With side effects of
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Dox treatment on cancer patients, we need to understand and explore Cr supplementation's role
in alleviating Dox-induced cytotoxicity, which might improve cancer patients' quality of life.
Creatine and Doxorubicin
There is a possibility that Cr supplementation before and during Dox treatment might
alleviate Dox-induced cytotoxicity in cancer patients. Up to the present time, few studies
explored the role of Cr supplementation on DOX-induced cytotoxicity. In cultured
cardiomyocytes incubated with a 5 nmol/L solution of Cr for 24 hours followed by a 1.5 µmol/L
of Dox, results reported Cr decreased Dox-induced cellular damage and protected
cardiomyocytes from Dox-induced cytotoxicity (Santacruz et al., 2015). Creatine
supplementation's molecular mechanisms might be due to its antioxidant and antiapoptotic
effects where the authors showed Cr supplementation reduced lactate dehydrogenase release,
ROS generation and decreases caspase 3 caspase 7, which are apoptotic markers (Santacruz et
al., 2015). An ex vivo study showed that Cr supplementation alleviated a decrease of force
production and maximal rate of force production in EDL muscle incubated with Dox and
protected against Dox-induced muscle fatigue in SOL and EDL muscles (Bredahl & Hydock,
2017). A preclinical study recently demonstrated that resistance exercise with Cr
supplementation delayed Dox-induced fatigue in skeletal muscles compared to either
intervention alone (Bredahl, Busekrus et al., 2020).
A study showed that Cr supplementation increased the survival rate in rats that were fed 2
mg/kg of Cr per day for 30 days before 15 mg/kg of Dox (Santos et al., 2007). The same study
also showed that Cr supplementation decreased cellular damage markers like serum lactate
dehydrogenase and creatinine levels. Recently, one study demonstrated that two weeks of 3% Cr
feeding alleviated a reduction in grip strength and an increase in fatigue in rats receiving 15
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mg/kg of Dox treatment (Torok et al., 2020). The explanation for the protection of Cr against
Dox-induced myotoxicity might be due to Cr supplementation enhancing the PCr/CK system
with increasing levels of PCr and ATP, which improves myosin ATPase activity and increases
force production (Greenhaff et al., 1994; van Leemputte et al., 1999; Wallimann et al., 2011;
Wyss & Kaddurah-Daouk, 2000). A high level of PCr and ATP also enhanced SERCA pump
activity and prevented Ca2+ accumulation, which might explain Cr supplementation's protective
effect against Dox-induced fatigue (Pulido et al., 1998; Tokarska-Schlattner, Zaugg et al., 2006;
Wallimann et al., 2011). Several studies demonstrated that Cr supplementation stimulated the
generation and regeneration of skeletal muscle fibers through MRFs expression and satellite cell
upregulation (Dangott et al., 2000; Willoughby & Rosene, 2003). Creatine supplementation also
has an antioxidant effect that acts to scavenge ROS and attenuates the oxidation of DNA and
lipid peroxidation (Guimarães-Ferreira et al., 2012; Lawler et al., 2002; Rahimi, 2011; Sestili et
al., 2011). Altogether, these data showed the possible role of Cr supplementation in combating
Dox-induced cytotoxicity and improving cancer patients' quality of life.
Conclusion
It is well-known that Dox treatment, one of the most widely prescribed drugs used in
oncology, negatively impacts cancer patients' quality of life. Doxorubicin induces toxicities
including cardiotoxicity and myotoxicity (Carvalho et al., 2009; Hayward & Hydock, 2007;
Hydock et al., 2011; Thorn et al., 2011). Impairment of the PCr/CK system might be one of the
Dox-induced cytotoxicity mechanisms (Azuma et al., 1981; Darrabie et al., 2011; Shneyvays et
al., 2001; Tokarska-Schlattner, Walliman et al., 2006; Tokarska-Schlattner, Zaugg et al., 2006).
More recently, literature reported that Cr supplementation might have a potential therapeutic role
in cardiovascular diseases, muscular diseases, and neurological diseases (Balestrino & Adriano,
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2019a, 2019b; Balestrino et al., 2016; Dedeoglu et al., 2003; Gualano et al., 2010; Passaquin et
al., 2002; Persky & Brazeau, 2001; Tarnopolsky et al., 2004; Wyss & Kaddurah-Daouk, 2000;
Zervou et al., 2015). Even more, Cr supplementation is safe, well-tolerated, decreases tumor
growth, and augments cancer therapy (Di Biase et al., 2019; Fairman et al., 2019; Miller et al.,
1993; Pal et al., 2016; Patra et al., 2012). One of the potential therapeutic mechanisms of the Cr
supplementation is to augment the PCr/CK system by increasing muscle Cr, PCr, CK-M, MtCK,
and CrT expression, thereby increasing ATP production and availability, which boost SERCA,
Ca2+ homeostasis, and contractility of muscle (Cooke et al., 2009; Hespel et al., 2001; Lygate et
al., 2012, 2013; Saks, 2008; Wallimann et al., 2011; Wyss & Kaddurah-Daouk, 2000). Increased
MtCK expression might enhance MPT, protect the mitochondria, and prevent apoptosis
(Brdiczka et al., 2006; Dolder et al., 2003; Wallimann et al., 2011). Therefore, Cr
supplementation might be of value when used as a non-pharmacological therapeutic intervention
to alleviate Dox-induced cytotoxicity.
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CHAPTER III
METHODOLOGY
Purpose of the Study
The purpose of this study was to examine the effects of different doses of dietary creatine
supplementation before doxorubicin treatment on CK enzymes and CrT protein expression in
cardiac and skeletal muscle.
Experimental Design
This study was an experimental research design that examined the effects of two different
Cr supplementation protocols before Dox treatment on CK and CrT expression in rat cardiac and
skeletal muscle. The current study examined and explored (a) the main drug effect of Dox
treatment on MtCK, CK-M, and CrT expressions in cardiac and skeletal muscles of rats; (b) the
main diet effect of two different Cr supplementation doses treatment on MtCK, CK-M, and CrT
expression in cardiac and skeletal muscles of rats; and (c) the interaction between Cr
supplementation and Dox treatment on MtCK, CK-M, and CrT expression in rat cardiac and
skeletal muscles. After four weeks of two different Cr supplementation protocols, rats received
either a 15 mg/kg injection of Dox or an equivalent volume of sterile saline (Sal). Lastly, five
days post-injection, rats were sacrificed and LV (cardiac muscle), EDL (fast-twitch muscle
fibers), SOL (slow-twitch muscle fibers), and DIA (major muscle of respiration) muscles were
excised, flash-frozen in liquid nitrogen, and stored at -80ᵒC for biochemical analysis. The
expression of MtCK, CK-M, and CrT was quantified using Western blotting and significant
effects were verified using enzyme-linked immunosorbent assays (ELISA).
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Animals
All procedures were approved by the Institutional Animal Care and Use Committee at the
University of Northern Colorado (see Appendix A) and complied with the Animal Welfare Act.
Sixty male Sprague-Dawley rats (10 weeks old) were obtained from Envigo, formerly Harlan
Laboratories. Using a male rat model to remove the confounding variable of female sex
hormones as estrogens are cardioprotective and myoprotective, which could influence the Doxinduced cytotoxicity (Booth et al., 2008; Persky et al., 2000). The target sample size for each
group was 10 rats. Data obtained from previous reports were used to calculate sample sizes
(Gibson et al., 2014; Hydock et al., 2011). Required sample sizes obtained from control and 15
mg/kg Dox groups analyzed five days following injections were calculated using two sample
means with the assumptions of normal distribution and unequal variance to obtain a power of
80% at α = 0.05. The calculated required sample size was eight per group. However, because the
study sample calculated did not include the effects of Cr on Dox-induced cytotoxicity, the
required sample size was set to 10 per group to more sensitively identify the protective effects of
Cr on Dox-induced cytotoxicity.
All rats were housed individually in a temperature-controlled facility with a 12-hour
light/12-hour dark cycle. Rats were provided nutritional interventions and water ad libitum. Rats
were randomly assigned to one of two four-week Cr feeding interventions (creatine protocol 1 or
creatine protocol 2) or a four-week standard rodent chow diet group (control). Rats in creatine
protocol 1 (Cr1, n = 20) were fed rodent chow (Teklad 2016, Envigo, Livermore, CA)
supplemented with 2% creatine monohydrate ad libitum for four weeks. It was reported that four
weeks with 2% Cr increased plasma Cr and intramuscular PCr in rats (Deminice & Jordao, 2012;
Deminice et al., 2009). Rats in creatine protocol 2 (Cr2, n = 20) were fed rodent chow
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supplemented (Teklad 2016) with 4% creatine monohydrate ad libitum for one week followed
by rodent chow supplemented (Teklad 2016) with 2% creatine monohydrate ad libitum for three
weeks. The second creatine protocol represented the loading and maintenance phases in humans,
thus increasing rat intramuscular free Cr and PCr (Deminice et al., 2009; Hultman et al., 1996).
Rats assigned to the control feeding group (Con, n = 20) were fed standard rodent chow (Teklad
2016).
After the four-week nutritional interventions, rats were further randomized to receive
either a bolus 15 mg/kg intraperitoneal Dox injection (doxorubicin hydrochloride, Wedgewood
Pharmacy, Swedesboro, NJ) or a bolus sterile saline (0.9% NaCl) intraperitoneal injection at an
identical volume as the Dox dose was a placebo (Sal). More specifically, the control rats were
assigned to receive Dox (Con+Dox, n = 10) or Sal (Con+Sal, n = 10), the rats in creatine
protocol 1 were assigned to receive Dox (Cr1+Dox, n=10) or Sal (Cr1+Sal, n = 10), and the
creatine protocol 2 rats were assigned to receive Dox (Cr2+Dox, n = 10) or Sal (Cr2+Sal, n =
10). The study design is illustated in Figure 4. The Dox injection dose was calculated by
multiplying the rat body weight by 15 mg, then dividing by 1000 g. This Dox dose has been
shown previously (15 mg/kg) to cause cardiotoxicity and skeletal muscle damage in rats (Gibson
et al., 2014; Hydock et al., 2011). Following injections, rats continued with the same assigned
nutritional intervention and on the fifth day after injections, rats were sacrificed. The body mass
(BM) of rats and the food intake were measured weekly throughout the entire study period. On
the first day of the study, 250 mg of food was put on the roof of the cage and every week the
food amount was measured; we added the deficit food amount to 250 mg.
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Figure 4
Experimental Design

Note. Con, control diet (standard rat chow); Cr1, rodent chow supplemented with 2% creatine
monohydrate for four weeks; Cr2, rodent chow supplemented with 4% creatine monohydrate for
one week + rodent chow supplemented with 2% creatine monohydrate chow for three weeks;
Sal, sterile saline injection; Dox, 15 mg/kg bolus doxorubicin injection.

In Vivo Muscle Function
Skeletal muscle function was analyzed in vivo using a commercially available grip
strength meter designed for rats (Columbus Instruments, Columbus, OH). The rodent forelimb
grip (FG) strength test is a procedure commonly used to analyze overall animal function and
assess neuromuscular function in toxicology studies (Heath et al., 2010; Horner et al., 2004;
Hübler et al., 2005; Seale et al., 2012). Beginning on the first day of the nutritional intervention
(before introducing Cr diets), FG strength was measured as described previously by our
laboratory (Torok et al., 2020). The procedure involved allowing each rat to grasp a pull-bar
attached to a force transducer with the front paws and once the rat had a secure grip on the pullbar, the technician pulled the rat away from the force transducer in a slow and steady manner
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until the rat released the pull-bar. During the trial, the force transducer measured the force
applied to the pull-bar and recorded the highest value achieved (typically, the force generated
just before releasing the pull-bar). Each rat was returned to its cage and allowed a five-minute
recovery before the ensuing trial. Forelimb grip strength was measured four more times (five
total measurements with five minutes rest between each trial) for each rat using the same
procedures. The mean of all five trials was used as the animal’s grip strength for that session
Tissue Collection and Storage
On the fifth day post-injection, rats were anaesthetized with sodium pentobarbital (50
mg/kg) administered intraperitoneally along with 500 U of sodium heparin serving as an
anticoagulant. After a tail pinch reflex was absent, the heart was rapidly excised and the
ascending aorta was cannulated for retrograde perfusion with Krebs–Hansleit (KH) buffer to
clear the blood in the coronary arteries (Gibson et al., 2014; Wonders et al., 2008). The LV was
then isolated, weighed, and immediately flash-frozen in liquid nitrogen and stored at -80°C for
ensuing biochemical analysis. The extensor digitorum longus (EDL) muscle, the soleus (SOL)
muscle from the left hind limb, and the diaphragm (DIA) muscle were then excised, weighed,
and immediately flash-frozen in liquid nitrogen and stored at -80°C until biochemical analysis.
Biochemical Analyses
Homogenate Preparation and Standardizing
Protein Concentration
The LV and skeletal muscles (SOL, EDL, and DIA) from each animal were homogenized
at a 10:1 ratio in radioimmunoprecipitation assay buffer (RIPA) with a protease enzyme inhibitor
(Santa Cruz Biotechnology) using a glass tissue homogenizer (Cole-Parmer PTFE tissue grinder)
and sonicated with 10, 1-second bursts (Fisher Scientific model 100 sonic dismembrator;
Waltham, MA). Homogenates were centrifuged for 10 minutes at 10,000 g (Eppendorf MiniSpin
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Centrifuges; Vernon Hills, IL), and the supernatant was decanted to a new tube. Total protein
was quantified by a Bradford assay using a Genesys 20 spectrophotometer (ThermoSpectronic:
Rochester, NY) at 595 nm. Protein concentrations were standardized for all samples by adding
RIPA buffer and Laemmli Sample Buffer was added to samples to prepare proteins for
electrophoresis (Bass et al., 2017; Bradford, 1976; Gibson et al., 2014).
Western Blotting
Western blot analysis was conducted to quantify the expression of MtCK, CK-M, and
CrT in the LV, SOL, EDL, and DIA. The prepared samples were boiled in water for two minutes
and placed on ice for 10 minutes; 40 µg of protein was loaded onto polyacrylamide SDS-PAGE
4-20 % gradient Tris-Glycine precast gels (ThermoFisher Scientific). In addition, 10 µl of
SeeBlue® Plus2 protein ladder and MagicMark™ XP Western Protein Standard (ThermoFisher
Scientific) were loaded onto gels to confirm the electrophoresis run and verify the molecular
weight of the proteins. Gel Electrophoresis was run at 125 V and 4 mA until proteins reached the
bottom of the gel (~two hours) in an Xcell II blot module (ThermoFisher Scientific). Proteins
were transferred to polyvinylidene fluoride (PVDF) membranes at 25 V and 100 mA for 90
minutes. Membranes were blocked with 10 ml of WesternBreezeTM Superblocker Solution
(ThermoFisher Scientific) for one hour. Membranes were then washed in water twice for five
minutes and incubated overnight in 10 mL of the specific primary antibody that included a
mouse monoclonal cytosolic CK-M antibody and sMtCK Antibody (Santa Cruz Biotechnology:
Dallas, TX) and a goat polyclonal CrT Anti-SLC6A8 antibody (Abcam: Cambridge, MA). The
mouse monoclonal anti-GAPDH (Santa Cruz Biotechnology: Dallas, TX) was used as a loading
control. On the second day, membranes were washed three times with Tris-Buffered Saline with
Tween 20 (TBSt) washing buffer followed by incubation in the appropriate species-specific
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secondary antibodies for one hour, and membranes were then rewashed with washing buffer to
prepare for protein band detection. The secondary antibodies, conjugated with horseradish
peroxidase (HRP), included Mouse IgG kappa binding protein (m-IgGκ BP) (Santa Cruz
Biotechnology: Dallas, TX) and Donkey Anti-Goat IgG H&L (Abcam: Cambridge, MA).
Protein expression detection included incubating the membranes with enhanced
chemiluminescence (ECL), 750 ml WesternBreeze TM Chemiluminescent Substrate Solution
(ThermoFisher Scientific), and 750 ml WesternBreeze TM Chemiluminescent Substrate
Enhancer for five minutes. Images were obtained using a C-Digit imager (LI-COR Biosciences:
Lincoln, NE). The protein bands' optical densities were then quantified using ImagJ software
(NIH: Bethesda, MD; Bass et al., 2017; Crone et al., 2019). The protein band density of primary
antibodies was divided by the GAPDH loading control's optical density for the final optical
density of CK-M, MtCK, and CrT expression.
Enzyme-Linked Immunosorbent Assays
The left ventrical was also analyzed for MtCK using ELISAs to verify western blotting
data. The LV was homogenized in Phosphate-buffered saline (PBS) buffer using a glass tissue
homogenizer (Cole-Parmer PTFE tissue grinder). Homogenates were centrifuged for five
minutes at 10,000 g (Eppendorf MiniSpin Centrifuges; Vernon Hills, IL), and the supernatant
was decanted to a new tube. A rat creatine kinase mitochondrial 2 (CKMT2) ELISA kit was used
to measure MtCK based on the manufacturer’s instructions. An antibody was pre-coated onto a
96-well plate and diluted standards were added to each well and allowed time to incubate.
Detection reagents A and B were added to each well and allowed to incubate.
Tetramethylbenzidine (TMB) substrate was used to quantify the HRP enzymatic reaction. The
optical density (OD) was measured spectrophotometrically at 450 nm using a microplate reader
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from which the concentration of MtCK was calculated. Assay was evaluated using a BioTek
microplate reader (ELx800; BioTek Instruments, Winooski, Vt., USA).
Data Analysis
Data are presented as mean ± standard error (M ± SEM). A two-factor (diet x drug)
analysis of variance (ANOVA) was used to determine the main diet effect, the main drug effect,
and diet x drug interaction of the dependent variables (food intake, BM, FG, LV mass, EDL
mass, SOL mass, DIA mass, MtCK, CK-M, and CrT). If a significant F value was observed,
Tukey’s post hoc testing was performed to identify where differences existed. Significance was
set at the α = 0.05 level.
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CHAPTER IV
RESULTS
Purpose of the Study
The purpose of this study was to examine the effects of different doses of dietary creatine
supplementation before doxorubicin treatment on CK enzymes and CrT protein expression in
cardiac and skeletal muscle.
Amount of Food Intake
The food intake during the study is presented in Table 1. Food intake was not
significantly different between groups in all four weeks before injections (p > .05); however, at
five days post-injection, Con+Dox (38±8 g), Cr1+Dox (3±0.5 g), and Cr2+Dox (6±1 g) amount
of food intake was significantly lower than Con+Sal (93±3 g; p < .05). Even though there was no
significant difference between Con+Sal (93±3 g), Cr1+Sal (93±3 g), and Cr2+Sal (96±5 g; p >
.05), both Cr1+Sal and Cr2+Sal was significantly higher than Con+Dox 5 days post-injection
(38±8 g; p < .05). Amount of food intake of Con+Dox was significantly higher than Cr1+Dox
(3±0.5 g) and Cr2+Dox (6±1 g; p < .05).
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Table 1
Amount of Food Intake
Con+Sal Con+Dox Cr1+Sal
st

Cr1+Dox

Cr2+Sal Cr2+Dox

1 week/Per day (g)

20±0.6

20±0.6

19±0.7

19±0.2

20±0.6

19±0.6

2nd week/Per day (g)

20±0.5

20±0.5

20±0.4

20±0.2

21±0.3

21±0.3

3rd week/Per day (g)

20±0.4

21±0.5

21±0.5

20±0.2

21±0.5

20±0.5

4th week/Per day (g)

16±2

17±1

17±2

17±1

17±1

16±1

5-days post-injection/Per day (g)

19±0.5

8±1*

19±0.6•

0.7±0.07*•

19±1•

1±0.3*•

Note. Data are Mean ± SEM. Con: Control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2:
creatine protocol 2; 1st: first week; 2nd: second week; 3rd: third week; 4th: fourth week.
*Significant different from Con+Sal (p < .05). •Significant different from Con+Dox (p < .05).

Animal Characteristics
Body masses at the start of the study, pre-injection, five days post-injection and LV and
skeletal muscle mass at the time of sacrifice are presented in Table 2. At the start of the study and
pre-injection days, BM was not significantly different between groups (p > .05); however, at five
days post-injection, Con+Dox BM (313 ± 9 g), Cr1+Dox BM (292 ± 3 g), and Cr2+Dox BM
(294 ± 9 g) were significantly lower than Con+Sal BM (348± 10 g; p < .05). Even though LV
mass of Con+Dox (597.5±30 mg) and Cr2+Dox (598±30 mg) were significantly lower than
Con+Sal (771±50 mg; p < .05), Cr1+Dox LV mass (638±40 mg) was not significantly different
from Con+Sal. There was no significant difference in SOL and DIA mass (p > .05); however,
EDL mass of Con+Dox (110±3 mg), Cr1+Dox (107±4 mg), and Cr2+Dox (108±3 mg) were
significantly lower than Con+Sal (134±5 mg; p < .05).
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Table 2
Animal Characteristics
Con+Sal

Con+Dox

Cr1+Sal Cr1+Dox Cr2+Sal Cr2+Dox

Starting BM (g)

290±9

292±5

298±4

300±3

292±4

294±3

Injection BM (g)

352±6

333±7

360±6

355±7

355±7

353±6

Sacrifice BM (g)

348±10

313±9*

358±9

292±3*

361±7

294±9*

Percent of BM changes

- 1%

- 6%

- 0.6%

- 18%

+ 1.7%

- 17%

LV mass (mg)

771±50

597.5±30*

762±50

638±40

744±30

598±30*

EDL mass (mg)

134±5

110±3*

142±4

107±4*

123±2

108±3*

SOL mass (mg)

128±4

131±6

135±4

123±4

139±7

121±4

DIA mass (mg)

198±20

177±15

210±22

181±17

187±17

222±15

Note. Data are Mean ± SEM. Con: Control; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine
protocol 2; BM: body mass week; LV: left ventricle; EDL: extensor digitorum longus muscle;
SOL: soleus muscle; DIA: diaphragm muscle, %: percentage; -: decrease; +: increase.
*Significantly different from Con+Sal (p < .05).

In Vivo Muscle Function
Forelimb grip force was not significantly different between groups at the first four weeks
and injection days (see Figure 5; p > .05). At five days post-injection, there was no significant
diet effect or interaction for FG force; however, a significant drug effect was observed for FG
force F(1, 54) = 64.00, p < .0001. Post hoc testing revealed the Con+Dox, Cr1+Dox, and
Cr2+Dox groups had significantly lower FG force than Con+Sal.
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Figure 5
Forelimb Grip Strength Test
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2;
Week 1: first week; Week 2: second week; Week 3: third week; Week 4: fourth week; Pre-Inj:
injection day; Post-Inj: 5 days post-injection. *Significantly different from Con+Sal (p < .05).

Biochemical Analyses
Western Blotting
Mitochondrial CK, CK-M, and CrT expression were measured in the LV, EDL, SOL, and
DIA muscle to examine the effect of Cr supplementation and Dox treatment on expression of
these proteins that played a role in the PCr/CK system. After optical density analysis, all
membranes were incubated in Ponceau S staining for 10 minutes to confirm no well loading
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volume variation. Images were obtained and analyzed using ImagJ software (NIH: Bethesda,
MD). There were no significant lane to lane differences in well loading protein.
Even though there was no significant diet effect on interaction for LV MtCK expression,
a significant drug effect existed for LV MtCK expression, F(1, 43) = 4.796, p = .0340 (see
Figure 6). Post hoc testing did not reveal differences existed. There were no significant main
effects or interaction observed for the LV CK-M and CrT expression in the LV (see Figures 7
and 8; p > .05).

Figure 6
Left Ventricle Mitochondrial Creatine Kinase Expression
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2.
*Significant drug effect (p < .05).
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Figure 7
Left Ventricle Cytosolic Creatine Kinase Expression
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2.
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Figure 8
Left Ventricle Creatine Transporter Expression
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2.

Regarding EDL muscle, SOL muscle, and DIA muscle, there were no significant main
effects observed and no interactions were detected for MtCK, CK-M, and CrT expression (see
Figures 9-17; p > .05).
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Figure 9
Extensor Digitorum Longus Muscle Mitochondrial Creatine Kinase Expression
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2

Figure 10
Extensor Digitorum Longus Muscle Cytosolic Creatine Kinase Expression Expression
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2.
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Figure 11
Extensor Digitorum Longus Muscle Creatine Transporter Expression
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2.

Figure 12
Soleus Muscle Mitochondrial Creatine Kinase Expression
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2.
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Figure 13
Soleus Muscle Cytosolic Creatine Kinase Expression
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2.

Figure 14
Soleus Muscle Creatine Transporter Expression
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2.
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Figure 15
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2.

Figure 16
Diaphragm Muscle Cytosolic Creatine Kinase Expression
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2
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Figure 17
Diaphragm Muscle Creatine Transporter Expression
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2.

Enzyme-Linked Immunosorbent
Assays
A mitochondrial 2 (CKMT2) ELISA kit was used to verify western blotting data of LV
MtCK expression. There was no significant diet effect observed for LV MtCK; however, a
significant drug effect, F(1, 52) = 5.059, p = .0288) and interaction, F(2, 52) = 4.056, p = .0231)
was observed for LV MtCK (see Figure 18). Post hoc testing revealed that the Cr2+Dox group
had significantly higher MtCK than Cr1+Sal and Cr2+Sal.
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Figure 18
Left Ventricle Mitochondrial Creatine Kinase Enzyme-Linked Immunosorbent Assay
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Note. Con: control; Sal: saline; Dox: doxorubicin; Cr1: protocol 1; Cr2: creatine protocol 2;
ng/ml: nanogram per milliliter. Significant drug effect (p < .05). Significantl interaction (p < .05).
*Significantly different than Cr2+Dox (p < .05).
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CHAPTER V
DISCUSSION AND CONCLUSIONS
Purpose of the Study
The purpose of this study was to examine the effects of different doses of dietary creatine
supplementation before doxorubicin treatment on CK enzymes and CrT protein expression in
cardiac and skeletal muscle.
Discussion
Doxorubicin is one of the most widely used chemotherapy drugs in oncology and is a
highly effective treatment for various cancers; however, it causes cardiotoxicity and myotoxicity
that can compromise quality of life and impair ADL in patients receiving Dox (Cortés-Funes &
Coronado, 2007; Hydock et al., 2011; Thorn et al., 2011). Creatine supplementation is a
promising non-pharmacological intervention where literature reported that Cr supplementation
might have a potential therapeutic role in cardiovascular diseases, muscular diseases, and
neurological diseases (Balestrino & Adriano, 2019a; Balestrino et al., 2016; Kreider et al., 2017;
Wyss & Kaddurah-Daouk, 2000; Zervou et al., 2015). Several preclinical studies also showed
that Cr supplementation decreased Dox-induced cellular damage, decreased markers of cellular
damage, protected against Dox-induced muscle fatigue, and alleviated FG impairments (Bredahl
& Hydock, 2016; Santacruz et al., 2015; Santos et al., 2007; Torok et al., 2020). With these
promising findings, it was imperative to explore mechanisms behind creatine's protection against
Dox-induced cardiotoxicity and myotoxicity through the phosphocreatine system. Understanding
the underlying mechanisms of Cr supplementation’s potential therapeutic effects is fundamental
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to help understand approaches to prevent and alleviate Dox-induced cytotoxicity in cancer
patients. This was the first study to examine the effects of two Cr supplementation protocols
before a bolus Dox treatment on cardiac and skeletal muscle phosphocreatine systems.
At five days post-injection, food intake was decreased significantly in animals that
received Dox treatment. The Con+Dox, Cr1+Dox, and Cr2+Dox groups ate 9±2 g, 0.7±0.1 g,
and 1±0.3 g, respectively, daily, and Con+Sal animals ate 19±0.5 g daily five days post-injection.
Even though the food intake for Cr1+Sal and Cr2+Sal was significantly higher than Con+Dox
animals, Cr supplementation did not enhance food intake nor alleviate the decrease in food
intake in rats receiving Dox treatment. A reduction in food intake might be due to the emesis.
Doxorubicin-induced emesis is a common side effect that harms the quality of life of cancer
patients (Ansari et al., 2016; Roscoe et al., 2010; Shih et al., 2009). The emesis might occur
within the first 24 hours after the first dose of chemotherapy (Morrow et al., 1996; Navari &
Aapro, 2016). The emesis occurs through peripheral and central pathways (Janelsins et al., 2013;
Navari & Aapro, 2016). The peripheral pathway starts at the enterochromaffin cells in the
intestine where they release serotonin to the terminal ends of the vagal afferents and binds to 5hydroxytryptamine (5-HT) receptors. Afferent fibers then transmit the stimuli to the brainstem,
which processes the emetic reflex and sends efferent signals to organs and tissues to induce
vomiting (Hesketh, 2008). The central pathway, located mainly in the area postrema of the brain,
is initiated after the first 24 hours after chemotherapy and is linked to neurotransmitter substance
P that activates neurokinin 1 (NK1) receptors in the central nervous system (Hesketh, 2008;
Navari & Aapro, 2016). Preclinical studies also provided evidence of the importance of
hindbrain areas that could initiate the emetic reflex after exposure to chemotherapy (Hesketh,
2008).
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Low food intake and energy restriction are accompanied by changes in circulating
hormones and mitochondrial efficiency slowing down basal metabolic rate to conserve energy
and minimize the energy deficit (Trexler et al., 2014). Reduction in the basal metabolic rate
might also be induced by reduced activity of the sympathetic nervous system, altered peripheral
thyroid metabolism, and lowered insulin secretion (Kurpad et al., 2005) where studies showed
that Dox treatment induced neuropathy, brain damage, and impaired pancreatic β-cell function
(Brady et al., 2021; Heart et al., 2016; Kuzu et al., 2018). A preclinical study showed a single
dose of Dox treatment (20 mg/kg) decreased BM, fat mass, fat-free mass, and oxygen
consumption in rats, which are associated with a decrease in total energy expenditure after 72
hours of Dox injection (Gilliam et al., 2013). Low energy expenditure might decrease overall
basal oxidative metabolism and disturb energy balance, which might be due to inhibition of the
mitochondrial respiratory chain, OP, energy stores, and MtCK activity (Gilliam et al., 2013; Yen
et al., 1999). A decrease in energy expenditure from different causes is closely related to cardiac
injury and cardiomyopathy (Jia et al., 2018; Wang et al., 2019). Altogether, low food intake and
energy expenditure might play a pathological role in Dox-induced cardiotoxicity.
Five days post-injection, Dox treatment significantly decreased BM, LV mass, and EDL
mass when compared to Con+Sal and was consistent with previous studies (Hydock et al., 2011;
Torok et al., 2020; Wonders et al., 2008). The body mass of Con+Dox animals was decreased
6% five days post-injection. Loss of BM and EDL mass suggested the Dox treatment played a
role in cancer cachexia and skeletal muscle atrophy in patients receiving Dox treatment (Argilés
et al., 2014; Hiensch et al., 2019). Loss of LV mass also suggested the Dox treatment played a
role in acute cardiotoxicity in patients receiving Dox treatment (Lefrak et al., 1973; Ma et al.,
2020; Shi et al., 2011; Simůnek et al., 2009). Body mass and muscle mass reduction might be
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driven by the emesis and diarrhea induced by Dox treatment (Navari & Aapro, 2016; Stein et al.,
2010). In addition, Dox-induced emesis with abnormal metabolism plays a role in cancer
cachexia (Fearon et al., 2011). Skeletal muscle atrophy occurs due to decreased protein synthesis
and increased protein degradation. Reduced protein synthesis is most likely driven by an altered
response to growth‐promoting pathways whereas increased protein degradation is mainly driven
by oxidative stress, autophagy, and activation of the UPP (Doerr et al., 2020; Hiensch et al.,
2019). The exact molecular mechanisms behind Dox‐induced muscle atrophy, however, are
currently not fully understood.
Four weeks before Dox treatment, Cr supplementation protocols did not increase BM and
muscle mass (Cr1+Sal and Cr2+Sal), which is consistent with previous preclinical studies
(Ferreira et al., 2005; Torok et al., 2020). In addition, five days post-injection, BM of Cr1+Dox
and Cr2+Dox animals was decreased 18% and 17%, respectively, suggesting Cr supplementation
increased BM loss with Dox treatment. Four weeks of Cr supplementation protocols did not
prevent BM loss and EDL mass loss in rats receiving Dox treatment. These results suggested Cr
supplementation alone did not increase BM and muscle mass. Contrary, ISSN reported weight
gain was the only consistent side effect from Cr supplementation (Kreider et al., 2017) and other
clinical studies showed that loading Cr supplementation increased BM and total body water
(Powers et al., 2003). The study, however, did not report food and fluid intake and subjects were
involved in an individualized resistance training program. However, a preclinical study
demonstrated that Cr supplementation alone did not increase muscle mass but resistance exercise
alone did increase muscle mass. This effect, however, was much more prominent when
combined with Cr supplementation (Ferreira et al., 2005). Several clinical studies also showed
that Cr supplementation with resistance exercise increased BM and free-fat mass (Antonio &
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Ciccone, 2013; Kreider, 2003; Kreider et al., 2017; Rodriguez et al., 2009b). Therefore, we
recommend that future research explore Cr's effect combined with resistance exercise on body
composition and muscle mass in Dox-induced atrophy. Curiously, the Cr2 supplementation
protocol did not preserve LV mass but the Cr1 supplementation protocol did preserve LV mass
in rats receiving Dox treatment, suggesting Cr supplementation might have a role in alleviating
Dox-induced cardiotoxicity, which might be dose dependent.
Regarding in vivo muscle function, a FG force decrease was prominent five days
following Dox injection and was consistent with a previous study (Bredahl, Sharif et al., 2020),
suggesting that FG force reduction was one of the manifestations of Dox-induced skeletal muscle
dysfunction. Four weeks of Cr supplementation did not enhance FG force nor alleviate the
decrease in FG force in rats receiving Dox treatment. In this study, Cr supplementation did not
increase skeletal muscle strength, which might be because Cr supplementation also could not
increase skeletal muscle mass. These results suggested that Cr supplementation alone without
exercise could not enhance strength and fat-free mass along with Dox treatment consistent with
the ergogenic aid literature (Cooper et al., 2012). One clinical study showed that Cr
supplementation alone without exercise did not enhance muscle glycogen storage (Sewell et al.,
2008). Combined Cr supplementation with resistance exercise, however, increased muscle
availability of Cr, PCr, glycogen stores and induced hypertrophy, which altogether enhanced
skeletal muscle strength (Antonio & Ciccone, 2013; Cooper et al., 2012; Kreider et al., 2017).
The hypertrophy induced by Cr supplementation with resistance training might result from
reduced protein degradation, increased synthesis rate of myosin and actin contractile proteins,
increased IGF-1, increased MRF proteins, and increased satellite cell mitotic activity (Dangott et
al., 2000; Deldicque et al., 2007; Ingwall et al., 1975; Louis et al., 2004; Willoughby & Rosene,
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2003). Therefore, it is again recommended that future research explore Cr's effect combined with
resistance exercise and Dox treatment on skeletal muscle strength
The current study's findings showed no drug effect, diet effect, or interactions were
observed for CK-M and CrT expression in the LV. Western blot and ELISA results showed a
drug effect for MtCK in the LV and there was no diet effect. Even though western bloting
showed no interaction, ELISA revealed a diet x drug interaction for MtCK in the LV. A decrease
in LV MtCK expression in rats receiving Dox treatment was consistent with results of many
studies that showed Dox treatment caused structural damage, inactivation of cardiac CK
isoforms, and reduction of mRNA of the CK isoform in cardiac cells treated with Dox treatment
(DeAtley et al., 1999; Ito et al., 1990; Mihm et al., 2001; Robison et al., 1989; TokarskaSchlattner, Zaugg et al., 2006b; Torti et al., 1998). These results suggested that MtCK
impairment and loss of LV mass might be one mechanism of Dox-induced cardiotoxicity.
Interestingly, one of the Dox mechanisms of action in cancer cells is it binds to
mitochondrial cardiolipin and blocks the association among MtCK, ANT, and VDAC (Carvalho
et al., 2009), which suggests an overlap between therapeutic and toxicity responses of Dox
treatment. In healthy mitochondria, binding of ANT and MtCK enhances ATP delivery into the
cytosol and influx of ADP to the mitochondrial matrix to be phosphorylated and, at the same
time, an influx of cytosolic Cr through VDAC drives the synthesis of PCr from ATP by MtCK
without loss of energy content (Dolder et al., 2003; Guimarães-Ferreira, 2014). The
mitochondrial CK, ANT and VDAC complex maintains maximal thermodynamic efficiency for
high-energy phosphate synthesis and channeling that is exported into the cytosol in the form of
PCr. Mitochondrial CK impairment and dissociation of MtCK from the mitochondrial membrane
might lead to a low influx of ADP to the matrix F0F1-ATPase and low ATP production by OP
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(Tokarska-Schlattner et al., 2007). Several studies also showed that Dox treatment inhibited OP
and inactivated mitochondrial F0F1-ATPase, causing low production of mitochondrial ATP
(Bianchi et al., 1987; Cheneval et al., 1983; Wallace, 2003). At the same time, MtCK impairment
might slow transphosphorylation of ATP into PCr, which leaves the mitochondria through
VDAC and feeds into the sizeable cytosolic PCr pool (Schlattner et al., 1998; Wallimann et al.,
1992, 2011). In addition, MtCK impairment might alter ATP/ADP exchange at the inner
mitochondrial membrane and affect the respiratory chain's proper function, which leads to low
ATP production and more ROS generation (Wallimann et al., 2011). Mitochondrial CK
impairment might lead to low PCr and PCr/ATP ratio in cardiac muscle.
Since ATP's source in cardiac muscle is mainly from the mitochondria (Ventura-Clapier
et al., 2004), Dox treatment might negatively impact the PCr/CK system through MtCK
impairment. The PCr/CK system promotes rapid resynthesis of ATP, reduces large increases in
ADP and H+, and provides a temporal and spatial energy buffer to maintain cellular energy
homeostasis in cardiac muscle (Guimarães-Ferreira, 2014; Sahlin & Harris, 2011; Wallimann et
al., 2011). Therefore, low production and release of PCr from the mitochondria might impair
resynthesis of ATP, leading to the accumulation of ADP and H+ in the cytosol. Accumulation of
ADP and H+ inhibits ATP hydrolysis and ATPase activity, which impair muscle contraction
along with many other cellular processes in cardiac muscle (Wallimann et al., 2011). A low ATP
production and availability might also negatively affect myofibrillar actomyosin ATPase,
SERCA, Na+/K+-ATPase, and Ca2+ ATPase and lead to impairment of contraction and relaxation
of cardiac muscle and accumulation of Ca2+ (Agteresch et al., 1999; Kitzenberg et al., 2016;
Saks, 2008).
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Several studies showed Dox treatment decreased ATP production, PCr, and PCr/ATP
ratio in cardiac muscle (Azuma et al., 1981; Pelikan et al., 1986; Sayed-Ahmed et al., 2000;
Shneyvays et al., 2001). Doxorubicin inhibits glucose uptake and PFK, down-regulates fatty acid
oxidation, inhibits the respiratory chain, OP, and inactivates F0F1-ATPase, which altogether
cause low production of mitochondrial ATP in cardiac muscle (Bianchi et al., 1987; Jeyaseelan
et al., 1997; Marcillat et al., 1989; Nicolay & de Kruijff, 1987; Sayed-Ahmed et al., 1999). In
addition, MtCK impairment might cause low ATP production by decreasing ATP/ADP
exchange, impairing the respiratory chain, and impeding ATP transphosphorylation into PCr
(Wallimann et al., 2011).
Mitochondrial CK impairment not only disturbs cellular energy homeostasis in
cardiomyocytes and the shuttle system but also affects OP, the electron transport chain, and the
MPT which lead to the initiation of apoptosis and cell death (Schlattner et al., 1998, 2006).
Doxorubicin-cardiolipin binding impairs membrane properties and thus changes the function of
several crucial mitochondrial membrane proteins like cytochrome c oxidase, inorganic phosphate
carrier, and ANT (Beyer & Klingenberg, 1985; Cheneval et al., 1983; Das & Mazumdar, 2000;
Demant, 1991; Goormaghtigh et al., 1982). Doxorubicin-cardiolipin binding within the inner
mitochondrial membrane also disrupts redox balance, causing myofibrillar protein oxidation and
breakdown of the contractile apparatus (Gilliam et al., 2013; Goormaghtigh et al., 1990; Min et
al., 2015; Tarpey et al., 2019). Mitochondrial CK impairment might alter the mechanical
stabilization of the mitochondrial membrane, impede lipid exchange between the two
membranes, and be involved in MPT opening (Dolder et al., 2003; Epand, Schlattner et al., 2007;
Speer et al., 2005). Opening the MPT is associated with apoptosis, which often leads to swelling
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of mitochondria, rupture, and release of apoptotic factors, eventually causing cardiac cell death
(Bauer & Murphy, 2020).
The mechanisms of Dox-induced cardiotoxicity are not entirely elucidated and it seems
multifactorial processes lead to cardiomyocyte death (Kalyanaraman et al., 2002; Minotti et al.,
2004). There is also an additional overlap between therapeutic and toxicity responses of Dox
treatment that share oxidative stress and apoptosis (Carvalho et al., 2009). Several studies
confirmed the standard mechanism of Dox-induced cardiotoxicity was due to increased oxidative
stress with increased ROS generation and labile intracellular iron (Chatterjee et al., 2010; Shi et
al., 2011; Takemura & Fujiwara, 2007). Even though Dox-induced increased ROS generation is
one of the main mechanisms to eradicate cancer cells, it also negatively impacts healthy tissue,
leading to cardiotoxicity and myotoxicity (Shi et al., 2011). An increase in ROS generation
causes lipid peroxidation, protein carbonyl formation, activation of the ubiquitin-proteasome
system, proteolysis, apoptosis, autophagy, and nuclear DNA damage, causing impairment of
cardiac function (Carvalho et al., 2009; Chatterjee et al., 2010; Singal et al., 2000). Even with the
commonly accepted ROS and iron theory as the primary mechanism of Dox-induced
cardiotoxicity, an antioxidant treatment failed to attenuate toxicity (Shi et al., 2011). Oxidative
stress and generation of ROS might lead to MtCK impairment and dissociation of MtCK
octamers into dimers (Carvalho et al., 2009; Tokarska-Schlattner et al., 2002, 2005). Oxidative
activation of the p-hydroquinone B ring by Dox treatment is necessary to oxidize sulfhydryl (SH)
groups of CK isoforms (Muraoka & Miura, 2004). Impairment of MtCK affects work
performance and Ca2+ homeostasis (Steeghs et al., 1997). Detrimentation of the PCr/CK system
causes energy depletion, reduction in PCr and ATP, leading to SERCA impairment, which
induces Ca2+ accumulation, more ROS generation, and apoptosis, and entering a vicious cycle
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with progressive impairment of CK isoforms (de Groof et al., 2002; Hamman et al., 1995;
Minajeva et al., 1996; Rossi et al., 1990; Soboll et al., 1999).
The current study's findings showed no diet effect for MtCK, CK-M and CrT expression
in the LV; however, an interaction was observed with MtCK in ELISA. This suggested four
weeks of Cr supplementation alone did not increase CKs and CrT in cardiac muscle; however, Cr
supplementation with Dox treatment increased MtCK, which might have a role in Dox-induced
toxicity. In the current study, cardiac muscle function was not measured; thus, we do not know if
Cr supplementation enhanced cardiac function. In addition, PCr was not measured in this study;
whereas several clinical studies showed intravenous PCr improved cardiac function and
prognosis in CAD (Balestrino et al., 2016; Ruda et al., 1988). Creatine supplementation also did
not attenuate left ventricular remodeling or prevent the decrease in total Cr in rat hearts postmyocardial infarction (Horn et al., 1999). One study showed Cr supplementation decreased
cytotoxicity, apoptosis, and ROS generation in cultured cardiomyocytes incubated with Dox
(Santacruz et al., 2015), which might be due to the antioxidant effect of Cr (Sestili et al., 2011).
In contrast, a preclinical study showed that Cr supplementation did not prevent ex vivo cardiac
function decline and had no effect on oxidative stress and apoptosis markers in mice isolated
heart perfused with Dox (Aksentijević et al., 2014). The effect of Cr supplementation on Doxinduced cardiotoxicity was not entirely elucidated. In the future, research needs to measure in
vivo and ex vivo cardiac function and measure PCr, Cr, CK quantity or activity, ATP, and ADP
to further understand Cr’s effect on cardiotoxicity through the PCr/CK system.
The current study's findings showed no drug effect for MtCK, CK-M and CrT expression
in skeletal muscle; however, a trend toward Dox treatment leading to reduced MtCK, CK-M, and
CrT expression than Con+Sal group was observed. A previous preclinical study showed that
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multiple doses of Dox (3 mg/kg) for four weeks significantly decreased CK-M in the SOL
muscle (Bredahl, Sharif et al., 2020). In this study, a total dose of Dox was 12 mg/kg and it took
four weeks to observe a reduction in CK-M in rats receiving treatment. Preclinical studies also
showed that Dox-induced toxicity mainly occurred in a dose‐dependent manner, a timedependent manner, and was dependent on age of the subjects (Colombo et al., 1989; Gibson et
al., 2014; Hayward et al., 2013; Hydock et al., 2011). In addition, the clinical manifestation of
cardiotoxicity induced by Dox was based on patient age (Giantris et al., 1998). Myotoxicity
might also result from Dox-induced cardiotoxicity where cardiotoxicity caused reduced left
ventricular function, which might eventuate to heart failure, and cardiac dysfunction negatively
impacts skeletal muscle (Celik et al., 2009; Hydock et al., 2011; van Hees et al., 2007). One
study showed that Dox accumulation increased in cardiac muscle and EDL muscle with age but
not in SOL muscle in rats receiving Dox treatment (Gibson et al., 2014). In the same study, Dox
accumulation in cardiac muscle was higher than skeletal muscle, which might be why we did not
observe a significant drug effect on MtCK, CK-M, and CrT expression in skeletal muscles. Five
days post-injection might not be enough time to observe significant drug effect on MtCK, CK-M,
and CrT expression. A bolus dose of Dox (15 mg/kg) might also not be sufficient to decrease
CKs and CrT expression. In a clinical setting, cancer patients receive multiple doses of Dox
treatment along with other chemotherapy (A’Hern et al., 1993). In addition, according to the
statistical data, the risk for all cancers increases with age and the median age of cancer diagnosis
is 66 years (White et al., 2014) and the 10 week old rats used in the current study might not have
translated well to this population.
Even though the results showed no diet effect or interactions for MtCK, CK-M, and CrT
expression in the skeletal muscles, a trend toward Cr supplementation leading to higher MtCK
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expression than Con+Sal was observed in EDL, SOL, and DIA muscles. This suggested Cr
supplementation did not increase MtCK, CK-M, and CrT expression in skeletal muscles, which
might explain why four weeks of Cr supplementation alone could not increase skeletal muscle
mass nor muscle strength. Several studies showed that Cr supplementation amplified the effects
of resistance training for enhancing performance, muscle strength, and hypertrophy (Cooper et
al., 2012; Cribb et al., 2007; Demant & Rhodes, 1999; Kreider, 2003). Creatine supplementation
with resistance exercise increases muscle availability of Cr, PCr, glycogen stores and induced
hypertrophy, which altogether enhanced skeletal muscle strength (Antonio & Ciccone, 2013;
Cooper et al., 2012). Therefore, it is again recommended that future research explore Cr's effect
combined with exercise on myotoxicity induced by Dox treatment.
Although the mechanism and pathogenesis of Dox-induced myotoxicity are not well
known, they might be due to an increase in ROS generation, which stimulates apoptosis and
autophagy and activates the UPP disturbs Ca2+ homeostasis (Gilliam & Clair, 2011; Hiensch et
al., 2019). Impairment of Ca2+ homeostasis might help explain one element of Dox-induced
fatigue and skeletal muscle dysfunction (van Norren et al., 2009). Both ex vivo and in vivo
studies showed that Cr supplementation alleviated the decrease of force production and delayed
Dox-induced fatigue (Bredahl, Busekrus et al., 2020; Torok et al., 2020). Preserving skeletal
muscle function and delaying Dox-induced fatigue with Cr supplementation might be due to Cr's
antioxidant effects scavenging and decreasing ROS generation (Guimarães-Ferreira et al., 2012;
Lawler et al., 2002). Creatine supplementation also improved intracellular Ca2+ homeostasis by
enhancing SERCA activity, thus increasing Ca2+ uptake by the sarcoendoplasmic reticulum
(Bazzucchi et al., 2009; Pulido et al., 1998). In addition, Cr supplementation augmented the
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PCr/CK system by increasing PCr/ATP ratio, enhancing PCr upsurge availability and resynthesis
of ATP, and facilitating intracellular energy transport (Wallimann et al., 2011).
The current study had several limitations that must be addressed before clinical
recommendations can be made in future research. The first limitation in the current study was the
sex factor where an entirely male rat model was used to remove the confounding variable of sex
effects on Dox toxicity. Mechanisms for sex differences in Dox‐induced cytotoxicity are not well
understood (Montalvo et al., 2021). The physiological factors that mediate sex differences in the
development of Dox‐induced cytotoxicity include differences in sex hormones, redox balance,
proteolytic activation, and deviation in Dox clearance (Montalvo et al., 2021). Female sex
hormone estrogens are cardioprotective and myoprotective, which could influence Dox-induced
cytotoxicity (Booth et al., 2008; Persky et al., 2000), and one study revealed that males produced
more mitochondrial ROS than females acutely following Dox treatment (Jang et al., 2004). A
review also concluded that muscle mitochondria in females differed in oxidative capacity,
resistance to oxidative stress, and Ca2+ homeostasis (Ventura-Clapier et al., 2017). Therefore,
future studies should use both female and male animals to examine sex difference effects on
Dox-induced cytotoxicity.
The second limitation was using healthy animals. Creatine supplementation has an
antioxidant effect (Sestili et al., 2011) and it is necessary to ensure that Cr does not disturb the
antineoplastic effects of Dox on cancer cells. Even though several studies with different
experimental models have shown that Cr supplementation has a potential anticancer effect,
enhances the effectiveness of an anticancer drug, and decreases tumor size (Ghosh et al., 2006;
Kornacker et al., 2001; Pal et al., 2016; Wyss & Kaddurah-Daouk, 2000), a recent study showed
that Cr promoted cancer metastasis in an orthotopic mouse models (Zhang et al., 2021). In
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addition, overexpression of MtCK enhances survival and inhibits the onset of apoptosis of breast
cancer cells (Qian et al., 2012; Yan, 2016). Therefore, in future studies, Cr supplementation with
Dox treatment should be applied in tumor-bearing models to examine and understand its effects
on cancer cells.
Ultimately, this study used Cr supplementation before a single dose of Dox treatment,
which did not provide a genuine replicate of the clinical setting. Therefore, future studies should
use Cr supplementation before and during multiple Dox doses, mimicking Dox treatment's
clinical use. Additionally, we did not measure intramuscular PCr, Cr, ATP, or CK quantity or
activity, which would be needed to understand how Cr supplementation affects Dox-induced
cytotoxicity throughout the PCr/CK system.
In summary, this was the first study exploring the effects of Cr supplementation before
Dox treatment on MtCK, CK-M, and CrT expression in rat cardiac and skeletal muscle. The
current study showed a bolus dose of Dox (15 mg/kg) decreased food intake, BM, LV mass,
EDL mass, FG force, and LV MtCK expression 5 days post-injection. Although the results did
not show that Cr supplementation protected against Dox-induced loss of BM and EDL mass and
decreases in FG force, it did demonstrate that Cr1 attenuated loss of LV mass and increased
MtCK in the LV with Dox treatment. This suggested Cr supplementation might have a role in
alleviating Dox-induced cardiotoxicity. Although more research is warranted, the results
provided support for Cr supplementation's potential and promising role as a palliative treatment
in improving QOL and enhancing ADL in cancer patients through attenuating cytotoxicity.
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